
==== Front
MedComm (2020)
MedComm (2020)
10.1002/(ISSN)2688-2663
MCO2
MedComm
2688-2663
John Wiley and Sons Inc. Hoboken

10.1002/mco2.709
MCO2709
Review
Review
Tumor‐associated exosomes in cancer progression and therapeutic targets
LIU et al.
Liu Xiaomin 1 2
Wu Fan 1
Pan Wei 1
Liu Guangchao 2
Zhang Hui 2
Yan Dawei 2
Zheng Saijing 2
Ma Zhongliang 1 zlma@shu.edu.cn

Ren Xiaojun 3 xjren@bjut.edu.cn

1 Lab for Noncoding RNA & Cancer School of Life Sciences Shanghai University Shanghai China
2 Shanghai New Tobacco Product Research Institute Co., Ltd. Shanghai China
3 Department of Chemistry College of Chemistry and Life Sciences Beijing University of Technology Beijing China
* Correspondence
Zhongliang Ma, Lab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai 200444, China.
Email: zlma@shu.edu.cn
Xiaojun Ren, Department of Chemistry, College of Chemistry and Life Sciences, Beijing University of Technology, Beijing 100124, China.
Email: xjren@bjut.edu.cn

07 9 2024
9 2024
5 9 10.1002/mco2.v5.9 e70905 8 2024
11 9 2023
06 8 2024
© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Exosomes are small membrane vesicles that are released by cells into the extracellular environment. Tumor‐associated exosomes (TAEs) are extracellular vesicles that play a significant role in cancer progression by mediating intercellular communication and contributing to various hallmarks of cancer. These vesicles carry a cargo of proteins, lipids, nucleic acids, and other biomolecules that can be transferred to recipient cells, modifying their behavior and promoting tumor growth, angiogenesis, immune modulation, and drug resistance. Several potential therapeutic targets within the TAEs cargo have been identified, including oncogenic proteins, miRNAs, tumor‐associated antigens, immune checkpoint proteins, drug resistance proteins, and tissue factor. In this review, we will systematically summarize the biogenesis, composition, and function of TAEs in cancer progression and highlight potential therapeutic targets. Considering the complexity of exosome‐mediated signaling and the pleiotropic effects of exosome cargoes has challenge in developing effective therapeutic strategies. Further research is needed to fully understand the role of TAEs in cancer and to develop effective therapies that target them. In particular, the development of strategies to block TAEs release, target TAEs cargo, inhibit TAEs uptake, and modulate TAEs content could provide novel approaches to cancer treatment.

1. Generalized the biogenesis, composition, and function of tumor‐associated exosomes (TAEs) in cancer progression.

2. Highlight potential therapeutic targets of TAEs.

3. TAEs are emerging as important mediators of cancer progression and potential therapeutic targets.

cancer progression
regulation
therapeutic targets
tumor‐associated exosomes
National Key Research and Development Program of China 10.13039/501100012166 2022YFA1603701 National Natural Science Foundation of China 10.13039/501100001809 22274004 Shanghai Science and Technology Committee 10.13039/501100003399 20S11901300 R&D Program of Beijing Municipal Education CommissionKM202310005015 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:07.09.2024
Liu X , Wu F , Pan W , et al. Tumor‐associated exosomes in cancer progression and therapeutic targets. MedComm. 2024;5 :e709. 10.1002/mco2.709
==== Body
pmc1 INTRODUCTION

With the gradual improvement of detection methods, targeted therapies, and immunotherapy, the mortality rate of cancer patients has decreased somewhat. 1 , 2 Nevertheless, cancer continues to be the leading cause of death for both males and females in US statistics. 3 The American Cancer Society's recently released “Blueprint for Cancer Prevention and Mortality Reduction 2030” emphasizes three key elements of cancer mortality reduction: prevention, screening, and treatment. 4 Targeted therapy is an important means to achieve targeted early treatment of malignant tumors, but there are fewer mature therapies targeted that can be used to guide clinical practice. Several methods have been proposed for early diagnosis and treatment of cancer, 5 but their clinical opportunity is still unknown due to the lack of standardized tests and high testing costs. 6 , 7 Therefore, the search for new stable and reliable targeted therapies for tumors remains an urgent problem in oncology research, which will aid in its diagnosis and treatment.

Exosomes are cell‐secreted nanoparticles (approximately 40–160 nm) that are involved in several functions such as intercellular communications, biological processes, and cell signaling. 8 , 9 The biogenesis and functionality of exosomes have been described, such as containing a variety of biologically active molecules to function, removing excess or unnecessary components from cells to maintain cell homeostasis, and serving as tools for intercellular material and information exchange. 10 , 11 A variety of functional biomolecules in donor cells are delivered and internalized by exosomes to perform functions such as gene regulation and modification of protein factors in recipient cells. Cancer‐associated factors in lung cancer have been shown to be associated with onset, metastasis, treatment, and prognosis through the transfer and recruitment of lung cancer‐derived exosomes to other cells. 12 , 13 Due to the surface alterability and good biocompatibility of endogenous exosomes, they are widely used as vehicles for drug delivery compared with liposomes. 14 Studies have shown that extracellular vesicles (EVs) containing the CRISPR/Cas9 gene editing system were targeted by aptamers recruitment to the lesion for precise gene editing for cancer treatment. 15 Thus, in the future, exosomes could serve as vectors for drug delivery, offering a potential treatment choice for cancer.

Exosome is a nanoscale bilayer lipid inclusions structure that can carry characteristic biological information molecules of the parent cell, such as proteins, lipids, deoxyribonucleic acid (DNA), mRNA, noncoding RNAs (ncRNAs), and so on, which are widely existed in body fluids, including blood, tears, urine, saliva, breast milk, and ascitic fluid. Of these, ncRNAs, including microRNAs (miRNAs), circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), tRNA‐derived RNA fragments (tRFs), and other common RNA fragments with some other specific functions, have complex interactions with each other. 16 They are mainly centered on miRNAs, forming a network of interactions that target genes and profoundly affect transcriptional and expression activities. 17 The progression of cancer involves multiple interactions of ncRNAs, which key nodes of the ncRNAs network may play a role in promoting or suppressing cancer. 18 Therefore, ncRNAs are considered to be important biomarkers and potential treatment targets for cancer. 19 Tumor‐derived exosomes contain ncRNAs with highly reactive activity to cancer‐promoting stress conditions such as hypoxia, 20 and they are regarded to be crucial elements in regulating lung carcinogenesis in cellular communication. 21 , 22 Due to the deliverability and modifiability of exosomes, they are suitable for carrying oncogenic ncRNAs to target cancer cells, and the bilayer membrane of exosomes ensures that ncRNAs are not degraded. 23 In current clinical diagnosis and therapy, tumor‐derived exosomes‐ncRNAs have potential significance. 24

In this review, we summarize the characteristics of exosomes, the role of tumor‐associated exosomes (TAEs) and nucleic acid (ncRNAs) in cancer progression, and emphasize the therapeutic targeting of TAEs. With the continuous progress of science and technology and the depth of clinical trials, we have reason to believe that exosomes will become one of the important tools for cancer treatment in the future.

2 CHARACTERISTICS AND IDENTIFICATION OF EXOSOMES

Exosomes, approximately 40–160 nm in size, are a class of EVs wrapped in a phospholipid bilayer and secreted by almost all eukaryotic cells that encapsulate abundant active biomolecules and compounds. 25 Exosomes are very heterogeneous due to their biogenesis involving heterogeneous membrane invaginations, differences in surface functional proteins and inclusions, and the influence of the different cellular microenvironments in which they are secreted. 8 In addition, the different internalization mechanisms of recipient cells allow exosomes to exhibit more complex biological functions.

2.1 Mechanisms of exosome formation in tumor cells

The mechanisms of exosome genesis include the formation of intracellular bodies, the formation of multivesicular bodies (MVBs) and secretion. Intraluminal vesicles (ILVs) formed in MVBs are the precursors of exosomes. Cytoplasmic membrane undergoes invagination and wraps around the cell membrane surface binding proteins with some components of the extracellular matrix. This process forms early sorting endosomes. RNA derived from the nucleus with ribonucleoprotein (RNP), golgi‐sorted protein, and lipid components enter the late sorting endosomes after maturation, forming MVBs that house multiple ILVs containing multiple bioactive molecules. 26 , 27 The formation of ILVs and MVBs was intricately regulated by signaling molecules, containing classical pathway dependent on endosome sorting complex required for transport (ESCRT) 28 versus the ESCRT‐independent lipid valve‐induced pathway. 29 Subsequently, these MVBs either fuse with lysosomes, leading to degradation, or with the plasma membrane, leading to the release of their internal vesicles, that is, exosomes. 30

2.2 Composition of exosome cargo and its functional roles in cancer progression

More and more studies have shown that exosomes are involved in malignant phenotypes of cancer, such as proliferation, metastasis, and drug resistance, in addition to epithelial–mesenchymal transition (EMT), angiogenesis, and other processes. Exosomes are widely distributed and studies have detected exosomes from tumor tissues and cells. It has also been found that exosomes can exchange substances between tumor cells or tumor microenvironment (TME), thus exerting a cancer‐promoting or cancer‐suppressing effect. Exosomes released by tumor cells, such as miRNAs, circRNA, and lncRNAs, are important mediators of cell–cell communication in the TME and have recently been demonstrated to play an important role in the regulation and communication of tumor development and progression. 8 Here, we will briefly describe the role of ncRNAs function, and we will elaborate later.

Studies have indicated that miR‐21 carried in exosomes produced by hepatocellular carcinoma (HCC) cells could convert hepatic stellate cells into tumor‐associated fibroblasts, thereby promoting cancer progression. 31 HCC cells could evade tumor immune surveillance via exosomes and could also promote growth and survival via exosomal‐cyclic RNA produced by adipocytes. 32 , 33 Cheng et al. 34 showed that HCC cell‐derived exosomes can act on macrophages to reduce the secretion of IL‐6, IL‐1β, IL‐10, and TNF‐α, thereby activating the signal transduction and activator of transcription 3 (STAT3) pathway and upregulating PD‐L1 expression. HCC cell‐derived exosomes containing miR‐92b could inhibit CD69 expression, counteract the cytotoxic effects of NK cells, and reduce T lymphocyte activation. 34 , 35 Zhu et al. 36 demonstrated that exosome miR‐106a was able to induce MMT to promote peritoneal metastasis of gastric cancer (GC) by activating the TGF‐β pathway through targeting Smad7 and tissue inhibitory factor of metalloproteinases 2. Study demonstrated that nicotinamide N‐methyltransferase‐containing exosomes from GC cells promoted peritoneal metastasis through TGF‐β/Smad2 signaling. 37 Kimura et al. 38 found that exosome miR‐29b from mesenchymal stem cells (MSCs) was able to inhibit peritoneal metastasis of GC by inhibiting MMT by blocking TGF‐β1 signaling. Qiu et al. 39 verified that exosome miR‐519a‐3p promoted GC liver metastasis by activating the dual‐specificity phosphatase 2‐mitogen‐activated protein kinase (MAPK)/extracellular signal‐regulated kinase (ERK) axis in intrahepatic macrophages. Yang et al. found that the exosome‐circRNA ubiquitin splicing enzyme E2Q2 (circ UBE2Q2) could inhibit autophagy and promote glycolysis, activate STAT3 signaling pathway and EMT, and promote GC liver metastasis. 40 Zhang et al. verified that exosome circFCHO2 activated JANUS kinase 194 (JAK194)/STAT5 pathway by sponging miR‐1‐3p and promoted GC lung metastasis. 41 Study also reported that lncRNAs are involved in tumor angiogenesis, which is an important link in maintaining tumorigenesis and promoting tumor metastasis. 42 The exosome‐derived lncRNA FAM225A further enhanced the expression of NETO2 and FOXP1 by regulating miR‐206, thereby promoting esophageal squamous cell carcinoma progression and angiogenesis. It has been shown that exosome‐derived lncRNA RPPH1 can act on β‐III microtubule proteins and exert an inhibitory effect on their ubiquitination, which can induce the production of EMT in colorectal cancer (CRC) cells, and consequently, participate in the process of CRC progression and metastasis in vivo. 43 The exosome circPABPC1 induces EMT production and promotes CRC liver metastasis by promoting the expression of HMGA2 in the nucleus as well as playing a role in the cytoplasm of BMP4 and ADAM19. 44 Fibroblasts are the most abundant stromal cell population in a variety of tumors and are closely related to tumorigenesis and progression, whereas cancer‐associated fibroblasts (CAFs) are formed by the transformation of normal fibroblasts induced by tumor cell‐derived exosomes. Compared with normal cells, the exosomes of CAFs contain different molecules, such as growth factors and miRNAs, which have different effects on target cells in the TME and can stimulate tumor growth and metastasis. 45 Tang et al. 46 revealed that miR‐208a could affect the proliferation and radiosensitization of human lung cancer cells through exosomal translocation, which in turn targets p21. Fan et al. 47 found that the proangiogenic effect of exosome miR‐210, a source of lung cancer cells, on CAFs may be through the modulation of the JAK2/STAT3 signaling pathway and TET2 in CAFs. You et al. 48 demonstrated that exosomes derived from CAFs were associated with EMT in lung cancer cells, and their study found that CAFs were able to exosomally deliver SNAI1 molecular mechanism of delivering SNAI1 to recipient cancer cells, that is, lung cancer cells, which in turn induces EMT in cancer cells. Qi et al. 49 elucidated that plasma exosome miR‐660‐5p promotes tumor growth and metastasis in NSCLC. Macrophage‐derived exosomes stimulated by LPS were able to activate the TGF‐β/Smad2/3 signaling pathway, which increased the expression of EMT‐related proteins vimentin, sma, and Col1 in A549 cells. 50

2.3 Specific markers of tumor‐derived exosomes

Over the last two decades, several tetratransmembrane proteins, in particular CD63, CD81, and CD9, have been used as markers of exocytosis because of their accumulation in small EVs compared with whole‐cell lysates, as well as the steady‐state accumulation of CD63 in MVBs. However, their presence in other EVs has recently been observed. By capturing EVs specifically carrying CD63 or CD9 or CD81 and then analyzing their protein composition and enrichment for endosomal markers, it was proposed that EVs containing only CD9 or CD81 without CD63 may not form in endosomes, whereas those carrying CD63 along with one or two other tetraspanning proteins may correspond to endosome‐derived ectosomes. 51

In recent years, many studies have shown that exosomes play an important role in tumorigenesis, progression, and response to treatment and have been considered as potential predictive markers of treatment efficacy. 52 For example, after radiotherapy, tumor cells may release a number of exosomes associated with DNA damage and these exosomes can be used to assess how well a tumor responds to radiotherapy. In particular, exosomes contain a variety of tumor‐related protein markers, such as human epidermal growth factor receptor 2(HER2), EGFR, glypicans, integrin, and programmed death ligand 1 (PD‐L1). These markers are overexpressed or abnormally secreted in tumor cells, so detecting their levels in exosomes can help doctors diagnose the type of tumor and degree of progression more accurately. Not only that, these exosomal protein markers can also be used to predict tumor treatment response. The most typical study is that the dynamic change of plasma exosome PD‐L1 before and after anti‐PD‐1 treatment can be used as a predictive marker to monitor patients’ treatment response. 53 , 54

The tumor susceptibility gene 101 (TSG101) and the associated proteins ALG2‐interacting protein X are specific markers for exosome identification. 55 Some cells secrete exosomes without relying on any fine molecular regulation, which was a reflection of exosome heterogeneity. 56 After the formation of MVBs, degradative MVBs were translocated to lysosomes to be degraded and may be dependent on the binding of autophagosomes present in the cell. Degradation products are recycled by the cells. Based on the transport of the microtubule network and cytoskeleton, secretory MVBs are transported to and integrated with the phospholipid bilayer on the cell surface, where ILVs are released to form exosomes with lipid bilayers. 57

3 THE ROLE OF TAEs IN CANCER PROGRESSION

Among tumor progression, exosomes play a critical role in information exchange, serving as the medium of intercellular communication. 58 The progression of cancer cells is not random. Cancer cells will be filtrated by relevant molecular programs to select specific target organs and metastasized to appropriate target organs. Exosomes also act as a crucial role in physiological and pathological process. 59 , 60 On the one hand, the physiological response require maintenance of exosome secretion, 61 and the pathological state is characterized by exosomes‐induced carcinogenesis, proliferation, immunosuppression, migration, invasion, and angiogenesis. 62 , 63

3.1 Effects of exosome‐mediated communication on tumor growth and metastasis

TAEs, as important mediators of information transfer from tumor cells, regulate biomolecular interactions and gene expression through autocrine or paracrine secretion in tumor growth and migration, affecting tumor biological phenotypes, including the induction of inflammation, angiogenesis, and EMT, and ultimately regulating tumor growth and metastasis. 64 , 65 The process of tumor development requires the involvement of a variety of biological substances and TAEs participate in gene regulation by carrying them. Therefore, body fluids from cancer patients exhibit a higher concentration of exosomes compared with those from healthy indivisuals. 66 In preclinical studies, Liang et al. 67 indicated that inflammasome signaling is activated by tumor‐derived exosomal TRIM59, which regulates ABHD5 proteasomal degradation to promote tumor growth and accelerates cancer progression by secreting IL‐1β. In other words, these data studies indicated that exosomes play a significant role in cancer progression. 68

Dysregulation of signaling pathways mediates an overall change in the pattern of molecular regulatory networks, an important molecular biological mechanism mediated by multiple factors, and induces tumor growth and metastasis. 69 , 70 More and more evidence suggest that the growth of tumors is accelerated by excessive release of exosomes from tumor cells. 65 Research shown a CRC‐derived exosome containing human antigen R promotes lung cell proliferation by increasing the stability of mRNA for the cell cycle signaling pathway‐related factors c‐Myc and downregulating the expression of the cycle surveillance factor p21, altering the biological process. 71 In the progression of nasopharyngeal carcinomas (NPCs), tumor cells activate the Akt/ERK signaling pathway through the secretion of TAEs delivering Epstein–Barr virus‐encoded latent membrane protein 1, which promotes proliferative migration and neovascularization in NPCs. 72 Upregulation of Wnt5b is associated with cancer invasiveness. Chinese hamster ovary cells are activated by exosomes from A549 lung adenocarcinoma (LUAD) cells and their migration and proliferation is stimulated by exosomes derived from human pancreatic cancer (PC) cells, PANC‐1. Caco‐2/Wnt5b cells were induced to migrate and proliferate using Caco‐2 colon cancer cells, while A549 cells were stimulated by Wnt5b exosomes. 73 As a result of these findings, it can conclude that Wnt5b‐associated exosomes may be paracrine in their effect on cell migration and proliferation. Additionally, Huang et al. 74 found that M2‐like TAMs promote the migration and invasion of cancer cells through intercellular delivery of M2‐like macrophage‐derived exosomes (M2‐exos) in vitro and in vivo. They demonstrated that the effect of M2‐like macrophage‐mediated invasion and migration on NSCLC cells was significantly reduced after blocking ITG αVβ3. This study reveals blocking exosomal ITG αVβ3 could be a potential treatment option for preventing tumor metastasis.

3.2 Influence of tumor‐derived exosomes on the TME

TAEs promote the occurrence and development of cancer by increasing the formation of the cancer microenvironment, promoting the ability of tumor cell invasion and metastasis, and mediate tumor immuno‐suppression. 75 Cancer microenvironment consists of extracellular matrix, fibroblasts, and perivascular cells, especially highly active immune cells. 76 Studies have shown that exosomes from irradiated lung cancer cells regulated the migration of recipient cells by accelerating glycolytic process. 77 Some studies suggest that exosomes act as an important communication media between different cell types in the TME. 78 , 79 Exosomes, as a novel intercellular communication mechanism, can transfer bioactive molecules from one cell to another, resulting in the exchange of genetic information and reprogramming of recipient cells. 80 In addition, there is growing evidence that macrophages are the most abundant group of white blood cells in lung cancer and play a key role in every stage of cancer progression. 81 These tumor‐associated macrophages (TAMs) promote tumor transformation, tumor immune escape, and subsequent metastasis cascade. It follows that tumor‐associated exosomes can regulate tumor progression, such as invasion, metastasis, angiogenesis and immunosuppression, and thus regulate tumor development (Figure 1).

FIGURE 1 Tumor exosomal regulates cancer progression, like proliferation, invasion, metastasis, angiogenesis, and immunosuppression.

During tumor growth and migration, tumors undergo inflammatory (M1) and regulatory (M2) polarization by reprogramming the metabolism of TAMs, modulating gene expression, and altering immune properties. 82 They act as a crucial regulatory role in the TME for tumor development. M1 polarization of TAM mediates the inflammatory effects of tumors through the secretion of inflammatory factors such as TNF‐α and IL‐6 and exhibits a biological function to inhibit cancer. However, at the end stage of tumor development, the M1 polarization of TAM is often reprogrammed by tumor cells toward M2 characteristics, most notably through changes in membrane markers and secreted factors. M2 polarization is characterized by inhibition of inflammation, promotion of tumor growth and migration, and induction of drug resistance. Although TAMs exhibit an intermediate state between M1 and M2 in some specific states, M2 polarization is often the final destination of TAMs in tumor development. 83 , 84 Recent studies have demonstrated the existence of complex cellular communication mechanisms in tumor‐mediated polarization of TAMs. TAEs, as important cellular communication mediators, mediate the exchange of information between tumor cells and TAMs through the delivery of biomolecules, which in turn reprograms the metabolism and regulates gene expression of TAMs. 85 , 86 Therefore, the regulation of TAMs polarization at the stage of tumor development is crucial and TAE‐mediated cellular communication plays an important role.

As mentioned earlier, ncRNAs are extremely important information carriers in TAEs. In the TME, TAMs undergo changes in their biological properties in response to tumor development, and tumor‐derived ncRNAs are delivered via TAEs and mediate TAMs polarization. Among them, miRNAs are the most studied class and are delivered to TAMs to mediate gene silencing functions. Among gynecological tumors, triple‐negative breast cancer (TNBC) and ovarian cancer (OV) are the most serious types of cancer. miR‐184‐3p enters TAMs via tumor‐derived exosomes and targets EGR1 to inhibit the c‐Jun N‐terminal kinase (JNK) signaling pathway, inducing M2 polarization in TAMs and promoting TNBC growth and metastasis. 87 In the hypoxic TME, miR‐1225‐5p was enriched in tumor‐derived exosomes and downregulated the expression of Toll‐like receptor 2 expression (TLR2) to promote M2 polarization of TAMs, which promoted the development of OV through activation of the WNT signaling pathway. 88 Exosomes in the microenvironment of nervous system‐associated tumors undergo complex informational crosstalk with different neuronal cells and are significantly associated with the polarization of TAMs. For example, let‐7i‐5p and miR‐221‐3p induces M2 polarization and promotes medulloblastoma development by downregulating peroxisome proliferator activated receptor gamma (PPARγ) after delivery to TAMs via exosomes. 89 Among neurological tumors, the deadliest are gliomas. miR‐3591‐3p was significantly enriched in TAEs and targeted and downregulated the CBLB of TAMs, activating the JAK2/STAT3 and MAPK signaling pathways to cause M2 polarization and promote glioma progression. 90 TAMs are important players involved in the gradual regulation of the TME in the development of CRC, which are usually regulated by TAEs. miR‐934 is highly expressed in CRC‐derived exosomes and is translocated to TAMs to silence PTEN as well as activate the phosphatidylinositol 3‐kinase (PI3K)/AKT signaling pathway to promote M2 polarization. Meanwhile, TAMs induced CRC to produce miR‐934‐rich exosomes by secreting CXCL13 positively counteracting the regulatory effects of CRC. 91 They promote the EMT process and migration of CRC by participating in the regulation of the TME. The TME is particularly important for the regulation of lung cancer development. For example, LUAD translocates miR‐19b‐3p via exosomes, downregulates PTPRD in TAMs and mediates activation of STAT3 dephosphorylation, leading to M2 polarization. LUAD inhibits its proteasomal degradation through exosomal transport of miR‐19b‐3p, which downregulates PTPRD and mediates STAT3 dephosphorylation activation in TAMs, 92 as well as transport of miR‐3153, which downregulates zinc finger protein 91 in TAMs, resulting in deubiquitination of misshapen‐like kinase 1, inhibiting its proteasomal degradation pathway, activating the JNK signaling pathway, 93 ultimately leading to M2 polarization and promotes the development of LUAD. The mechanisms by which lncRNAs regulate TAMs via TAEs are mainly sponge adsorption of miRNAs and binding to critical protein factors. LINC00313 sponges miR‐135a‐3p through TAE transport and upregulates STAT6, inducing M2 polarization of TAMs and promoting NSCLC progression. 94 FGD5‐AS1 is enriched in PC‐derived exosomes and interacts with p300 of TAMs to activate the STAT3/NF‐κB pathway. 95 In clear cell renal cell carcinoma, AP000439.2, also delivered via exosomes, directly binds to STAT3 and activates the STAT3/NF‐κB pathway. 96 They both promote tumor development by causing M2 polarization of TAMs. CircRNAs are “genomic dark matter” and play a crucial role in regulating gene expression and tumor behavior. However, its role in TAMs through TAEs has been less studied. But there is no doubt that they are of potential research value.

The ontogeny of exosomal cargo is the formation of various factors in the cells that secrete exosomes through assembly. Thus, in addition to various nucleic acid molecules, protein factors function as a regulatory substance in TAEs and act in the TME by means of intercellular communication. In HCC, intratumoral proteasome subunit alpha 5 (PSMA5) acts on TAMs via exosomes to activate the JAK2/STAT3 signaling pathway and promote M2 polarization. 97 Similarly, in diffuse large B‐cell lymphoma (DLBCL), the subunit of the IL‐6 receptor, GP130, was significantly enriched in exosomes, activating STAT3 signaling and inducing M2 polarization in macrophages. 98 NADPH oxidase 1 promotes malignant transformation of cervical cancer by inducing reactive oxygen species (ROS) and is enriched in exosomes secreted by tumor cells, delivered to TAMs likewise inducing ROS activation and promoting M2 polarization. 99 The nucleotide‐binding oligomerization domain‐like receptor family pyrin domain‐containing 6 has a critical function in small cell lung cancer (SCLC) metastasis, where it acts on TAMs via SCLC‐secreted exosomes, inducing the activation of NF‐κB signaling and promoting M2 polarization. 100

In general, the M1 polarization of TAMs exhibits a strong proinflammatory function and strong phagocytosis, and it promotes the transformation and reprogramming of TAMs that have been polarized to M2 type to M1 type through the secretion of a variety of oncogenic active factors. However, in some specific TMEs, TAMs exhibit a mixture of M1 and M2 types, with M1‐type TAMs playing a role in promoting cancer migration. Obviously, this type of phenomenon is not consistent with the consensus that M1‐type TAMs promote inflammation and suppress cancer. 101 Moreover, such M1‐type TAMs are also regulated by TAEs. For example, in oral squamous cell carcinoma, thrombospondin 1 (THBS1) activates the p38, Akt, and SAPK/JNK signaling pathways of TAMs via TAEs and promotes M1 polarization of TAMs, but not M2 polarization. 102 Previously, attention has been focused on the M2 polarization of TAMs. This study reveals that the function of TAMs after polarization is not absolute, and that there may be uncovered regulatory mechanisms behind it. there is a more complex link between the polarization of TAMs and tumor progression.

In summary, the TME is very closely linked to the malignant development of tumors, as a result of mutually regulated positive feedback. In the TME, the polarization of TAMs is the most important influencing factor affecting its regulatory function. M2 polarization of TAMs is regulated by various factors such as signaling pathways, is promoted during tumor progression through TAEs, and is involved in inducing behaviors such as tumor proliferation and migration. This is an important reflection of the interaction between the TME and tumor development. Although, little is known about the M1 polarization of TAMs, it is undeniable that M1‐type TAMs have a strong regulatory function, especially in some specific environments exhibiting cancer malignancy induction, which contradicts previous findings and deserves our attention.

3.3 Contribution of exosomes to drug resistance and immune evasion in cancer

With the advent of the postchemotherapy era, target and immunotherapies have made milestones in the treatment of cancer. For example, immune checkpoint inhibitors, such as partial programmed death‐1/programmed death‐ligand 1 (PD‐1/PD‐L1) inhibitors with cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) inhibitors have been approved for marketing by the United States Food and Drug Administration and the rest are in clinical studies. 103 , 104 However, it is inevitable that cancer counteracts tumor drug resistance by altering epigenetic and metabolic reprogramming, greatly limiting the clinical application of novel drugs. 105 , 106 Therefore, the search for targets to overcome antitumor drug resistance has now become an urgent challenge. Researches have shown that TAEs regulate cancer gene expression through cellular communication, inducing the development of tumor resistance and often accompanied by tumor proliferative and migratory behaviours. 45 , 107 , 108 TAEs may be potential clinical therapeutic targets.

Under stress conditions, TAEs tend to contain components that induce tumor resistance to chemotherapeutic agents in order to modulate critical genes contributing to tumor resistance. In breast cancer (BC), chemotherapy‐induced secretion of miR‐378a‐3p and miR‐378d in exosomes is significantly upregulated and acts on adjacent BC cells, silencing Dickkopf 3 and NUMB and activating the stemness pathways of WNT and NOTCH, allowing BC to become chemoresistant. 109 In addition, cancers are inherently resistant to chemotherapeutic agents, altering their gene expression through TAEs in the setting of chemotherapeutic agents in order to produce acquired resistance. Tumor exosome‐derived miR‐1260b serves as a tumor‐communicating substance, silencing homeodomain‐interacting protein kinase‐2 expression in human umbilical vein endothelial cells (HUVECs), and promotes the migration of tumor cells with the emergence of chemotherapeutic resistance. 110 lncSBF2‐AS1 was significantly upregulated in glioblastoma (GBM) exosomes and translocated to adjacent GBM cells sponging miR‐151a‐3p, inducing the silencing deregulation of X‐ray repair cross complementing 4, and enhancing DNA double‐stand break repair, leading to chemoresistance. 111 The conventional lysosomal pathway or the ubiquitin‐proteasome degradation pathway leads to the degradation of oncoproteins in chemosensitive cancer cells. The development of chemoresistance is often accompanied by dysregulation of protein degradation mechanisms, leading to the accumulation of oncoproteins within the cell. Moreover, the resistance mechanism is transmitted to chemo‐sensitive cells by means of cellular communication to transform them into drug‐resistant cells. For example, resistant TNBCs are induced to be resistant to gemcitabine by delivering annexin A6 (ANXA6)‐rich, which results in the inhibition of EGFR ubiquitination degradation in chemotherapy‐sensitive cells. 112 Receptor–ligand interactions are not all direct, and TAEs act as an important mediator to mediate remote binding of receptors to ligands to amplify the impact of gene regulation. Resistant BC cells secrete exosomes enriched for the EPH receptor A2 (EphA2) protein, which translocates as a receptor to chemotherapy‐sensitive BC cells and binds Ephrin A1 ligand, thereby activating the downstream ERK1/2 signaling pathway and inducing chemotherapy resistance. 113 This is not the classical receptor–ligand binding mode, but an exosome‐mediated reverse binding pathway. Previous studies have reported that tumor metabolic reprogramming is an important cause of chemotherapeutic resistance, and lipid metabolic reprogramming and ferroptosis inhibition are the metabolic pathway modulations that have received the most attention for inducing chemotherapeutic resistance. 114 , 115 TAEs are important regulatory mediators in the process of metabolic reprogramming of tumors. GC‐secreted exosomes are enriched for lncFERO and translocate to GC stem cells to interact with SCD1 mRNA, recruit heterogeneous nuclear RNP A1 (hnRNPA1) to promote its expression, and inhibit ferroptosis and chemoresistance. 116 Previously, we described that TAEs promote tumor development by inducing the polarization of TAMs to interact with the TME. Indeed, M2 polarization of TAMs acts on tumor cells through a feedback mechanism and induces the development of chemoresistance. GBM exosomes are enriched for lnc‐TALC, translocate to the TME to promote M2 polarization in microglia and bind to Enolase 1 to promote MAPK phosphorylation and C5/C5a secretion, inhibit temozolomide‐mediated DNA damage, and induce chemoresistance. 117

Furthermore, exosomes are important mediators of immune regulation in cancer as they provide a plethora of signals that can support or suppress immunosuppression of lymphoid and myeloid cell populations in tumors. 118 Tumor‐derived exosomes promote the tumor immune response in two ways: on the one hand, by suppressing the function of dendritic cells (DCs), T cells, and NK cells. DCs, as mediators between innate and adaptive immune responses, play a crucial role in inducing the antitumor activity of T cells. DCs play an important role in the activation of the immune response. For example, exosomes produced by mouse BC cells target CD11b+ myeloid precursor cells in the bone marrow in vivo and inhibit their differentiation to DCs. 119 , 120 Lung cancer‐derived exosomes block DC differentiation by downregulating surface markers such as CD80, MHC‐II, and CD86 but upregulating the expression of CD11B and PD‐L1. 120 In addition, exosomes can also inhibit T cell proliferation by converting extracellular ATP to adenosine. Adenosine inhibits a wide range of immune cells and stromal cells; therefore, higher levels of adenosine in tumors contribute to the immunosuppressive microenvironment. Tumor‐derived exosomes carry the exonucleotidases CD39 and CD73 on their surface, which convert ATP into extracellular adenosine, thereby inhibiting T cell proliferation. 121 Study found that O‐GlcNAc transferase in the exosomes of esophageal cancer stem cells (ECSCs) was found to protect ECSCs from CD8+ T cell damage by upregulating PD‐1. 122 NKG2D (NK cell‐activated receptor NK group 2, member D) is an activation receptor for NK, NKT, and CD8+ T cells, and its aberrant loss in cancer is a key mechanism of immune evasion, and NKG2D may be an exosome‐mediated immune evasion in cancer. NKG2D may be a physiological target for exosome‐mediated cancer immune evasion. 123 The NKG2D receptor on NK cells is an important component of cancer immunosurveillance, as cancer cells typically express NKG2D ligands to varying degrees, signaling their response to NK cell‐mediated destruction. 124 Such as, cancer cell‐derived exosomes expressing ligands for TGFβ and NKG2D downregulate the expression of NKG2D on the surface of NK cells and CD8+ T cells, thereby blocking its activity. 125 On the other hand, tumor‐derived exosomes amplify the number of myeloid‐derived suppressor cells and regulatory T cells through various signaling pathways and stimulate macrophage polarization toward the procarcinogenic M2 phase. 126 For example, tumor exosomes convert myeloid cells into MD⁃SCs by secreting PGE2, TGFβ or IL6, TNFα, and CCL2. TGFβ upregulates Foxp3+ T‐regulatory cell production in tumor exosomes. 120 Finally, tumor‐derived exosomes may also advance cancer progression by developing xenogeneic satellite tumors alongside the primary tumor, which is called regional carcinogenesis, where morphological and molecular abnormalities occur around the tumor, although there are no obvious histological changes.

4 TAEs OF NUCLEIC ACID IN CANCER

With the rapid development of second‐generation sequencing technology, the research and clinical application of exosomal nucleic acids are also maturing. The sequencing of the human genome revealed that protein‐coding genes make up only 3% of human DNA, while more than 80% of the genome can be transcribed. These RNAs, which do not have the ability to code for proteins, are called ncRNAs. 127

As research continues to evolve, our understanding of ncRNAs has shifted from “Junk” transcripts to functional regulatory molecules that mediate cellular processes such as chromatin remodeling, transcription, posttranscriptional modification and signal transduction. 18 , 128 Thousands of individual ncRNAs within the cell can form networks that influence numerous molecular targets to drive specific cell biological responses. 129 As a key regulatory factor in physiological and disease processes, ncRNAs are closely related to tumors and have been identified as carcinogenic or tumor suppressor factors in a variety of cancer. 130 , 131 Many studies have shown that exosome ncRNAs have well stability due to the protective effect of exosome membranes. This stability holds great significance in the development of cancer. 132 , 133

In recent years, exosome‐derived miRNAs, lncRNAs, and other ncRNAs have attracted much attention in the field of cancer research worldwide. Thus, we summarize the roles of ncRNAs (with a focus on miRNA and lncRNA) in exosome ncRNAs in cancer. This summary aids to increase our understanding of the function of exosome ncRNAs in cancer and provide a basis for the development of antitumor therapeutic strategies based on exosome ncRNAs.

4.1 Exosmal miRNA in cancer

Precursor miRNA is a small RNA molecule with hairpin structure formed by transcription of RNA polymerase II and cleavage by Drosha. Subsequently, it is cleaved into a mature miRNA of approximately 23 nt in length, a process that involves Dicer. Eventually, the mature miRNA forms a complex with the corresponding RNA‐induced silencing complex, which exerts an essential gene silencing function mainly by binding to the 3′‐UTR of mRNA. 134 Dysregulation of miRNAs promotes cancer development, and miRNAs are tightly associated with tumor metastasis in exosomes. 135 Therefore, miRNAs carried by exosomes are very important gene regulatory signals between cells communication and are thought to have the potential to inhibit the metastatic properties of cancer. 136 It was found that exosome secretion in lung cancer is regulated by signaling pathway such as LKB1 and AMPK/mTOR, which can promote cell motility. 137 Besides, the investigators provided a comprehensive summary of the value of exosomal miRNA in the clinical diagnosis of lung cancer patients with EGFR mutations and the specific treatment regimen, including development of targeted drugs. 138 In addition, there were more significant variations in the expression profiles of TAEs in metastatic cancer. 139 These miRNAs differentially expressed in exosomes are likely to be underlying biomarkers of cancer metastasis. Plasma is widely present, abundant, and easy to detect. miRNAs in plasma exosomes of lung cancer patients are often used as clinical markers. 140 Exosomal miRNAs derived from the plasma of lung cancer patients are often used as clinical diagnostic markers, including monitoring cancer metastases. 141 , 142 However, not all exosomal miRNAs have characterization value, which requires further validation. 143 , 144 , 145

Exosomal‐delivered miRNAs may mediate the progression of drug resistance. For example, miRNA‐130a expressed by cancer‐associated fibroblasts derived from TME in cancer was packaged into exosomes by mutual effecting with the RNA‐binding protein PUM2. Eventually, miRNA‐130a promotes resistance to chemotherapeutic agents in lung cancer. 146 In the case of EGFR mutations, clinically commonly treated with tyrosine kinase inhibitors are more likely to develop acquired resistance, which leads to metastasis of cancer. 147 Previous studies speculated that the upregulation of miRNA in exosomes might be related to this. Kakeru Hisakane et al. 148 identified exosomal miR‐210‐3p may promote acquired resistance to oxitinib in lung cancer cell lines and play a critical role in EMT. Due to the dense structure of tumors, the TME often reflects the characteristics of hypoxia. Exosome secretion under stressful conditions may have specific effects on cancer cells. Therefore, the hypoxic TME is closely associated with the occurrence and function of exosomes. High expression of miR‐625‐3p in exosomes of the hypoxic TME was internalized by lung cancer cells and binds to the 3′‐UTR of suppressor of cancer cell invasion and inhibited expression, eventually promoting lung cancer metastasis. 149 Compared with the metastasis‐regulating mechanisms described above, the internalization of exosomal miRNAs by lung cancer cells revealed is not a direct effect on vascular epithelial cells. Therefore, exosomal miRNAs may have a more direct mechanism to promote metastasis in a hypoxic environment. EMT is a critical developmental process for tumor cells. Epithelial tumor cells regulate transcription factors and signaling pathway transduction through gene mutations and epigenetic modifications to enhance migration, invasion, and resistance to apoptotic stimuli and drug. 150 , 151 EMT confers local invasive ability to epithelial tumor cells and is therefore an important indication of tumor metastasis. Lung cancer cells with high metastasis play a signaling function to promote EMT in epithelial cells by secreting exosomes. With these exosomes, miRNAs play a crucial role in regulating gene expression. For example, miR‐224‐5p derived from lung cancer cells is internalized by the normal lung cell line BEAS‐2B via exosomal delivery and targets androgen receptor to promote invasion, migration, and EMT process. 152 Derived from exosomes of highly metastatic lung cancer cells, miR‐499a‐5p enhances EMT in LUAD by activating the mTOR signaling pathway. 153 A common process in lung cancer development involves lung cancer cells with high drug resistance promoting EMT in epithelial tumor cells through exosomal delivery of signaling molecules. The osimertinib‐resistant NSCLC cell line HCC827‐OR, along with PC‐9‐OR, promotes EMT in osimertinib‐sensitive lung cancer cells by secreting exosomes delivering miR‐210‐3p. 148 In addition to this, it has been shown that some cells, such as MSCs, deliver message molecules via exosomes that perform the function of inhibiting EMT in lung cancer. MSCs deliver miR‐204 via exosomes and target Krüppel‐like factor 7 (KLF7) within the KLF7/AKT/HIF‐1α axis to inhibit EMT in cancer. 154

As of present, more than a thousand endogenous exosomal miRNAs have been identified with potential biological functions. Therefore, the functions of exosomes are absolutely not homogeneous. For example, a study revealed that the exosomal delivery of miRNA‐494‐3p secreted by lung cancer cell into HUVECs and inhibition of PTEN expression exhibited antiangiogenic effects variously. 155 In recent years, the therapeutic role of exosome miRNA in lung cancer has gained increasing attention, 156 meanwhile the clinical treatment strategy of combining exosomal miRNAs with chemotherapeutic agents. Li et al. 157 showed that exosomal miR‐613 secreted by lung cancer cells significantly enhanced the inhibitory effect of cisplatin on lung cancer and reversed the resistance of NSCLC to cisplatin. Moreover, the action of chemotherapeutic drugs may be closely associated with lung cancer exosome secretion. 157 A study showed that everolimus targeting mTORC1 exerts therapeutic effects while inducing the secretion of miR‐7‐5p in the form of exosomes in NSCLC. Intracellular expression of miR‐7‐5p is reduced, leading to the release of inhibition of MAPK interacting kinases/eukaryotic translation initiation factor 4E (MNK/eIF4E) axis, as well as the resistance of everolimus. 158 Therefore, induction of reinternalization of miR‐7‐5p‐containing exosomes in combination with everolimus is a potential clinical regimen for the treatment of NSCLC. In addition, engineering exosomes that introduce miRNAs with oncogenic effects may be a potential therapeutic strategy for future lung cancer clinics. Jeong et al. 159 used 2D and 3D microfluidic techniques showed that engineered exosomes containing miRNA‐497 significantly suppress tumor growth‐associated genes in NSCLC. Besides, posttranscriptional silencing of VEGFR‐2 and inhibition of angiogenesis were achieved after miRNA‐497 was delivered into HUVECs via exosomes. 159 This is an engineering exosome with potential clinical application.

Although exosomal miRNAs affecting cancer metastasis has been extensively explored for several years, more support and exploration are still needed toward the clinic. As mentioned before, in addition to developing new clinical diagnostic markers based on pivotal exosomes derived from cancer in regulating tumor metastasis, the combination of exosomal miRNAs with tumor metastasis therapy is also a direction worth exploring. How to further improve the targeting of engineered exosomes and combine them with traditional chemotherapeutic drugs to mitigate side effects is a hot topic of research now. miRNAs have received a lot of attention for cancer treatment, and there are already miRNAs moving toward clinical trials as drugs. 160 It is clear that exosome delivery is an effective solution to improve the stability of miRNAs. In the future, intensive studies of exosomal miRNAs may provide more reliable clinical candidates for the early diagnosis and treatment of cancer progression (summarized in Table 1).

TABLE 1 Exosomal and miRNAs related with cancer progression by regulating cell function.

Cancer type/disease	Exosomes source	miRNA	Related genes or pathway	Functions	References	
Lung cancer (NSCLC)	Lung cancer cells	miR‐934	circUSP7/SHP2	Promote resistance to anti‐PD1 immunotherapy 	161	
LUAD 	Lung cancer cells	miR‐19b‐3p	STAT3	Promote lung adenocarcinoma metastasis	92	
Lung cancer	Lung cancer cells	miR‐210	JAK2/STAT3 pathway	Proangiogenic factor	47	
Lung cancer	Lung cancer cells	miR‐4466	STAT3	Promotes tumor cell stemness and metabolism	162	
Colorectal cancer	Colorectal cancer cell	miR‐934	PI3K/AKT signaling	Induce M2 macrophage	163	
Breast cancer	Breast cancer cells	miR‐205	E2F1	Promotes chemoresistance	164	
Gastric cancer	Gastric cancer cells	miR‐501	BLID	Confers doxorubicin resistance and tumorigenesis	165	
Lung cancer (NSCLC)	Serum	miR‐660‐5p	KLF9	Promote proliferation and

migration

	49	
Lung cancer	Lung cancer cells	 miR‐3180‐3p	FOXP4	Inhibits metastasis and proliferation	166	
Lung cancer (NSCLC)	Paired tumor and normal tissue	miR‐4443	FSP1 m6A modification	Promote cisplatin resistance	167	
Abbreviations: circUSP7/SHP2, circular ubiquitin‐specific protease‐7/Src homology phosphatase 2; E2F1, E2F transcription factor 1; FOXP4, Forkhead Box P4; FSP1, ferroptosis suppressor protein 1; KLF9, Krüppel‐like factors 9; STAT3, signal transducer and activator of transcription 3.

John Wiley & Sons, Ltd.

4.2 Exosomal lncRNA in cancer

A ncRNA molecule with more than 200 nucleotides is known as a lncRNA, which can regulate gene expression at the transcriptional or posttranscriptional level, thereby regulating various biological processes such as tumor cell growth, metastasis, and treatment resistance. 168 Currently, numerous studies have demonstrated the connection between exosomal lncRNAs and the emergence of cancer. 169 , 170

Exosomes isolated from peripheral blood with NSCLC bone metastasis (BoM) were shown to be enriched in lncRNA–SOX2OT, according to research by Ni et al. 171 and cancer patient's overall survival was inversely linked with the expression level of lncRNA‐SOX2OT. They further revealed that exosomal lncRNA‐SOX2OT derived from NSCLC cells targeted the miRNA‐194‐5p/RAC1 signaling axis, the TGF‐/pTHrP/RANKL signaling pathway in osteoblasts to regulate osteoclast development and trigger NSCLC BoM. 171 Wu et al. 172 demonstrated that TGF‐β1‐mediated exosomes increased lung vascular endothelial cell permeability and tight junction protein downregulation via lnc‐MMP2‐2. Additionally, lncRNA–MMP2‐2 upregulated EPR41L5 expression through sponge miR‐1207‐5p. EPR41L5 indirectly promoted EMT, disrupted tight junctions, increased blood–brain barrier (BBB) permeability and ultimately contributed to NSCLC brain metastasis. 172 Studies also found that by targeting miR‐181a‐5p to control sirtuin 1 (SIRT1), Qu et al. 173 showed that exosomal lncRNA DACT3‐AS1 deletion produced from CAFs increased proliferation, migration, and invasion of GC cells. Furthermore, through the combined actions of iron death and apoptosis, DACT3‐AS1 sensitized GC cells to oxaliplatin; iron death was more important for oxaliplatin sensitivity. 173 Zhang et al. 174 showed that the level of lncRNA MALAT‐1 in serum exosomes of NSCLC patients is significantly increased, which can promote the growth and migration of lung tumor cells and inhibit their apoptosis. Feng et al. 175 identified exosome LINC00623 as a promising biomarker for the diagnosis of early pancreatic ductal adenocarcinoma (PDAC) with high specificity and sensitivity. The PDAC cells’ capacity for proliferation, tumorigenesis, migration, and invasion was supported by the LINC00623/NAT10 signaling axis. By modifying mRNA's N4‐acetylcytidine (ac4C) alterations, N‐acetyltransferase 10 (NAT10) improved oncogenic mRNA stability and translation in PDAC. 175 Han et al. 176 , 177 screened the highly expressed lncRNA AFAP1‐AS1 from a trastuzumab‐resistant strain using lncRNA microarrays. In his research, he revealed that knockdown of AFAP1‐AS1 reversed trastuzumab resistance through gain‐of‐function and loss‐of‐function assays. Furthermore, extracellular AFAP1‐AS1 was able to bind to exosomes and deliver trastuzumab resistance. By interacting with AUF1, AFAP1‐AS1 increased the translation of ERBB2 mRNA. This increased the amount of HER‐2 protein, which led to trastuzumab resistance. 176 , 177 The expression of lncRNA lincRNA‐p21 was significantly increased in hypoxic NSCLC cells (H23 and HCC44), which promoted angiogenesis and endothelial adhesion of tumor cells. 178 Cheng et al. 179 studies have shown that the level of lncRNA GAS5 (growth arrest‐specific 5) is not only low in lung cancer tissues and serum exosomes, but also significantly lower in lung cancer cells (A549, H1299 and 95D) and their exosomes than that of normal bronchial epithelial cells. lncRNA GAS5 can competitively bind miR‐29‐3p with PTEN which upregulating the expression of PTEN and inhibiting the PI3K/protein kinase B (PKB/AKT) pathway. Additionally, the expression levels of HOTAIR and GAS5 are both affected by exosome secretion, 180 and the downregulation of HOTAIR can increase NSCLC cell lines sensitivity to Crizotinib. 181 Additionally, lung cancer‐derived exosomal GAS5 (exo‐GAS5) affects the apoptosis, proliferation, and tube formation of HUVECs. 179

Drug resistance is a common clinical problem. Gefitinib and erlotinib belong to the generation of EGFR‐TKIs. Acquired drug resistance has become a major clinical problem with increasing use. Yu et al. 182 concluded that exosomal lncRNA LOC85009 decreased docetaxel (DTX) resistance and cell growth but induced apoptosis. In addition, exosomes are used to transfer LOC85009 from LUAD cells to DTX‐resistant LUAD cells. Exosomal LOC85009 induced death in DTX‐resistant cells while inhibiting proliferation, autophagy, and DTX resistance. By controlling ATG5‐induced autophagy via the ubiquitin‐specific proteinase 5 (USP5)/upstream transcription factor 1 (USF1) axis, LOC85009 reduced DTX resistance. 182 Through the development of a profeedback loop connected to the hnRNPA1/WNT5A/VEGFR3 regulatory axis, Zheng et al. 183 , 185 discovered a significant role for exosomal lncRNA BCYRN1 in bladder cancer's (BCa) lymphangiogenesis and lymph node (LN) metastasis. A new theory for how exosomal lncRNA induced tumor lymphatic metastasis was presented by the molecular mechanism by which exosomal BCYRN1 promoted LN metastasis of BCa in a VEGF‐C dependent way. 183 According to Chen et al., 184 human lymphatic vessel endothelial cells internalized exosomal lncRNA LNMAT2 after uptake, and this increased PROX1 expression by enlisting hnRNPA2B1 and boosting the amount of H3K4 trimethylation on the PROX1 promoter, ultimately causing lymphangiogenesis and BCa lymphatic metastasis. Feng et al. 175 identified exosome LINC00623 as a promising biomarker for the diagnosis of early PDAC with high specificity and sensitivity. The PDAC cells’ capacity for proliferation, tumorigenesis, migration, and invasion was supported by the LINC00623/NAT10 signaling axis. By modifying mRNA's ac4C alterations, NAT10 improved oncogenic mRNA stability and translation in PDAC. 175 Furthermore, extracellular AFAP1‐AS1 was able to bind to exosomes and deliver trastuzumab resistance. By interacting with AUF1, AFAP1‐AS1 increased the translation of ERBB2 mRNA. This increased the amount of HER‐2 protein, which led to trastuzumab resistance. 176 Wang et al. 186 identified an adenomatous polyposis coli (APC)‐activated lncRNA (lncRNA‐APC1), which could increase the expression of lncRNA‐APC1 by preventing PPAR enrichment at its promoter. By directly binding to Rab5b mRNA and decreasing its stability, lncRNA‐APC1 prevented exosome formation, which in turn prevented CRC cell proliferation, metastasis, and tumor angiogenesis. The MAPK pathway was activated in endothelial cells by exosomes from CRC cells that have been repressed by lncRNA‐APC1, and this was significant because it promoted angiogenesis. 186 Additionally, Lei et al. 187 found that lncRNA H19 expression was significantly increased in gefitinib resistant cell line, and heterogeneous nuclear RNP A2/B1(hnRNPA2B1) can transfer gefitinib resistance by binding to the 5′ end‐specific motif (GGAG) of lncRNA H19 and mediating its loading into exosomes. Studies have also shown that patients with high expression of serum exosome lncRNA RP11‐838N2‐4 have erlotinib resistance. Notably, the high expression of RP11‐838N2‐4 can significantly increase expression in erlotinib‐resistant cells, and transferring of RP11‐838N2‐4 through exosomes can induce resistance insensitive cells. 188

As the basic theories and applications of exosomal lncRNAs continue to be researched, exosomal lncRNAs will not only be used as biomarkers for early diagnosis, treatment monitoring, and prognosis assessment, but also as therapeutic targets for tumors, providing a novel approach to the accurate diagnosis and treatment of tumors. 189 It can be seen that lncRNAs derived from tumor cells can regulate the biological behavior of cells through various mechanisms and affect the angiogenesis and disease progression of cancer. Therefore, exosomal lncRNAs will have a broad application prospect in the field of tumor diagnosis and treatment (summarized in Table 2).

TABLE 2 Exosomal and lncRNAs related with cancer progression by regulating cell function.

Cancer type/disease	Exosomes source	lncRNA	Related genes or pathway	Functions	References	
Lung cancer (NSCLC)	Lung cancer cells	SOX2OT	miRNA‐194‐5p/RAC1	Regulate osteoclast development and trigger NSCLC BoM 	171	
Lung cancer (NSCLC)	Lung cancer cells	MMP2‐2	miRNA‐1207‐5p/EPB41L5	Promote NSCLC brain metastasis	172	
Lung cancer (NSCLC)	Lung cancer cells	MALAT‐1		Promote growth and migration, inhibits apoptosis	174	
LUAD	LUAD cell	LOC85009	USP5/USF1	Reduce docetaxel resistance	182	
Pancreatic cancer	Pancreatic cancer cells	LINC00623	NAT10	Promote pancreatic cancer progression	175	
Gastric cancer	Gastric cancer cells	DACT3‐AS1	miR‐181a‐5p/SIRT1	Promote ferroptosis‐mediated oxaliplatin resistance in GC	173	
Bladder cancer	Bladder cancer cells	BCYRN1	VEGF‐C	Drive lymphatic metastasis of bladder cancer	183	
Bladder cancer	Bladder cancer cells	LNMAT2	PROX1	Promote lymphatic metastasis in bladder cancer	184	
Colorectal cancer	Colorectal cancer cells	 APC1	Rab5b	Promote angiogenesis	186	
Lung cancer (NSCLC)	Lung cancer cells	AFAP1‐AS1	AUF1	Promote trastuzumab resistance	176	
Lung cancer	Lung cancer cells	lncRNA MMP2‐2	TGF‐β	Promote invasion and migration	190	
HUVECs	Lung cancer	GAS5	PTEN	Promotes tumor angiogenesis	179	
Lung cancer	Lung cancer cells	lncRNA H19	hnRNPA2B1	Promote gefitinib resistance by packaging into exosomes	187	
Lung cancer	Lung cancer cells	lncRNA RP11‐838N2. 4	FOXO1	Promote erlotinib‐resistant	188	
John Wiley & Sons, Ltd.

4.3 Other ncRNAs (circRNA/tRF) from exosome in cancer

Among exosomal, cancer is also closely associated with a number of other ncRNAs (circRNAs and tRF), except miRNAs and lncRNAs. circRNA is a new member of endogenous ncRNA, which is widely distributed and has diverse cell functions. Recently, circRNAs have been discovered due to their stability and enrichment in exosomes. 191 Studies have found that some circRNAs are associated with tumor development, progression, and drug resistance. Exosome and circRNA_101093 (cir93) are significant for insensitivity LUAD cells to ferroptosis in which blocking exosome may help with LUAD treatment. 192 Peng et al. 193 identified circRNA CD226 relies on regulation of the miR‐1224‐3p/HMGA2 axis as a potential driver of cancer development. Tumor‐derived exosomal circRNAs have been reported to be key circRNA in the process of EGFR‐TKIs resistance. Tumor‐derived exosomal circRNA_102481 may promote EGFR‐TKIs resistance in NSCLC via the miRNA‐30a‐5p/ROR1 axis. 194 Additionally, knockdown of exosomal circ_PIP5K1A could suppressed NSCLC development and promoted cisplatin sensitivity via regulating miR‐101/ABCC1 axis. 195 In LUAD patients, both the serum and serum exosomal circRNAs, hsa_circ_0001439, hsa_circ_0001492, and hsa_circ_0000896 were upregulated. Serum exosomal circRNAs may be a more effective biomarkers than serum circRNAs in the diagnosis of LUAD and may further benefit the detection of this disease. 196 Thus, exosomal circRNAs have potential applications as new therapeutic targets and disease biomarkers, although their specific roles and gene regulatory mechanisms require more investigation.

tRFs are also small RNAs that come from the 5′ end or 3′ end of the tRNA in a specific environment. 197 , 198 The biological function of the derived exosome tRFs is still ambiguous. Studies have found that the levels of exosomes tRFs (tRF‐Leu‐TAA‐005, tRF‐Asn‐GTT‐010, tRF‐Lys‐CTT‐049, tRF‐Ala‐AGC‐036, and tRF‐Trp‐CCA‐057) in patients with cancer are downregulated. 199 This suggests that these exosomal tRFs may be diagnostic biomarkers for cancer. Wang et al. 200 found that alveolar macrophage‐derived exosome tRF‐22‐8BWS7K092 can activate Hippo signaling pathway to induce iron apoptosis in acute lung injury, BALF exosomes in ALI mice are mainly derived from AMs. Currently, little is known about exosomal and TRF expression in cancer. Nonetheless, their biological functions have attracted the attention of many studies. In the future, exosomal tRFs may act as latent diagnostic biomarkers and therapy target in cancer.

5 THERAPEUTIC TARGETING OF TAEs

Exosomes have been shown to play a role in cancer progression and metastasis by promoting the exchange of genetic material and proteins between cancer cells and their microenvironment. However, exosomes can also be harnessed for therapeutic purposes, including the treatment of cancer. The multiple components and properties that exosomes can carry make them potential therapeutic targets in cancer therapy. Through in‐depth study of the mechanism of exosomes' role in cancer genesis, progression and drug resistance, and the development of therapeutic approaches against these targets, it is expected to bring new breakthroughs in cancer therapy.

5.1 Strategies for inhibiting exosome secretion and uptake in cancer cells

One potential application of exosome‐based therapies in cancer patients is the delivery of therapeutic agents directly to cancer cells. Exosomes can be engineered to carry drugs, small interfering RNA (siRNA), or other therapeutic molecules and can be targeted to specific cancer cells. 201 , 202 Such as exogenous siRNA to monocytes and lymphocytes in human blood cells, which exosomes can silence the MAPK1 gene. 203 , 204 This demonstrates that exosomes can deliver therapeutic RNA to target cells. This approach has the potential to increase the efficacy and specificity of cancer therapies while minimizing side effects. Another potential application of exosome‐based therapies is in the field of immunotherapy. 205 Tumor immunity usually refers to the activation of the immune system when immune cells infiltrate and come into contact with the tumor, and to the ongoing death of tumor cells to free up antigen. This is followed by the activation of T and NK cells and the production of antibodies to destroy the tumor cells. 206 , 207 Yang et al. 208 found that in glioma, tumor‐derived exosomes inhibit CD8+ T‐cell proliferation, immune cell activity, and IFN‐γ levels by inhibiting PEG3, thereby inhibiting glioma cell apoptosis and further enhancing glioma cell immune evasion through in vitro and in vivo experiments. M2 macrophages which secreted from exosomes significantly enhanced the proliferation and antiapoptotic ability of colon cancer. Lu et al. 209 found that FOXO3‐AKT/GSK3β pathway and the mechanism by which TAM‐derived exosomal miR‐29a‐3p upregulates PD‐L1 expression to facilitate OV cell proliferation and immune escape. This study is through inhibiting T‐cell activity and ultimately facilitating immune evasion. Moreover, the researchers showed that M2 macrophage‐derived exosomes can promote GC progression by activating the P38MAPK pathway, while also promoting high PD‐L1 expression in GC cells, which aids GC cells in immune evasion and leads to poor prognosis. 210 Therefore, to overcome the immune evasion of tumors, targeting exosomes derived from tumor may be an effective strategy.

Exosomes can be engineered to carry immune‐stimulatory molecules that can activate the immune system and promote an antitumor response which has shown promise in preclinical studies. 211 There are several challenges that need to be overcome to fully realize the potential of exosome‐based therapies in cancer patients. These include the optimization of exosome production and engineering, the identification of suitable cancer targets, and the development of strategies to overcome drug resistance and tumor heterogeneity.

5.2 Potential therapeutic targets within exosome cargo for cancer treatment

Exosomes are secreted by a variety of cells, including cancer cells, and carry a variety of molecules, including proteins, lipids, and nucleic acids. 188 , 212 These molecules, collectively referred to as the exosome “cargo,” can have significant effects on the TME and contribute to cancer progression and metastasis. Several potential therapeutic targets within exosome cargo have been identified for cancer treatment: (1) Oncogenic proteins: Exosomes can carry oncogenic proteins that promote cancer cell growth and survival. 213 Inhibiting the secretion or function of these proteins could be a potential therapeutic strategy. (2) miRNAs: Exosomes can carry miRNAs that regulate gene expression and promote cancer progression. Such, by secreting ACSL4‐targeting miRNAs produced from exosomes, CAFs inhibit ferroptosis and cause PC cells to become resistant to gemcitabine. 214 Inhibiting the secretion or function of these miRNAs could be a potential therapeutic strategy. (3) Tumor‐associated antigens (TAAs): Exosomes can carry TAAs, which are proteins that are overexpressed in cancer cells and can be recognized by the immune system. 215 Targeting TAAs with immune‐based therapies could be a potential therapeutic strategy. 216 (4) Immune checkpoint proteins: Exosomes can carry immune checkpoint proteins, such as programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), which can inhibit immune responses against cancer. 217 Blocking these proteins could be a potential therapeutic strategy. (5) Drug resistance proteins: Exosomes can carry proteins that contribute to drug resistance, such as P‐glycoprotein (P‐gp) and multidrug resistance‐associated protein 1. 218 Inhibiting the secretion or function of these proteins could be a potential therapeutic strategy. (6) Tissue factor (TF): Exosomes can carry TF, a protein that plays a role in blood clotting and can promote cancer metastasis. 219 Inhibiting TF function could be a potential therapeutic strategy. In summary, in combination with the characteristics of exosomes, their application in the treatment of cancer has mainly the following directions (Figure 2), the exosome cargo contains several potential therapeutic targets for cancer treatment.

FIGURE 2 Directions in exosome therapy for cancer. GEM, gemcitabine; GEM + PTX, gemcitabine + paclitaxel; P‐gp, P‐glycoprotein; MRP1, multidrug resistance‐associated protein 1; TAAs, tumor‐associated antigens.

Qiu et al. 39 found that GC exosomal miR‐519a‐3p promotes liver metastasis through induction of intrahepatic M2‐like macrophage‐mediated angiogenesis. This study provides experimental evidence supporting the potential therapeutic targeting of miR‐519a‐3p in GC. Moreover, researchers elucidated that tumor‐derived exosomal miR‐148b‐3p can be transported from BC cells to surrounding macrophages and induces M2 polarization by targeting TSC2, providing new insights for BC therapy. 220 These findings lay the groundwork for future research on BC potential therapy. Emerging evidence suggests that exosomes may act as cargo, facilitating intercellular communication and allowing tumor cells to signal surrounding stromal cells to alter cancer progression. 221 , 222 Even so, further research is needed to fully understand the role of these targets in cancer progression and to develop effective therapies that target them.

5.3 Clinical applications of exosome‐based therapies in cancer patients

At present, exosomes show great potential in clinical treatment of cancer because of their ability to carry and deliver important substances, including therapeutic molecules. Compared with traditional drug delivery systems, exosomes are biocompatible, low immunogenicity, and highly targeted. They are able to penetrate biological barriers, such as the BBB and deliver therapeutic molecules directly to the lesion site. 223 , 224 One of the important application directions is that exosomes can be used as biomarkers for cancer patients. Wei et al. 225 found that showed that the combination of exosome‐EphA2 + CA19‐9 + CA242 can not only improve the ability to diagnose PC at an early stage, but also improve the ability to differentiate PC from benign pancreatic diseases, using exosome‐EphA2 + CA19‐9 + carbohydrate antigen 242 (CA242) as an early diagnostic marker. Li et al. 226 demonstrated that serum exosome levels were significantly elevated in patients with OV compared with benign disease or healthy controls, and that 117 differentially expressed lncRNAs as well as 513 differentially expressed mRNAs were dysregulated in expression as revealed by mapping between mRNAs of exosome origin and those of corresponding tumor origin. Therefore, tailoring cancer treatment by analyzing the various ribonucleic acids contained in exosomes for risk assessment of patients may be achieved in the near future.

Additionally, exosomes as new drug carriers also have many advantages. Clinical trials on exosome therapies have already begun, such as the exosome group transporting a small molecule STING agonist, a phase I/II clinical trial for advanced solid tumors. 227 Jonathan et al. 228 reported that exosomes from the engineered melanoma cell contain survivin‐T34A and, alone or in combination with gemcitabine, significantly increased apoptotic cell death compared with gemcitabine alone in a variety of PC cell lines. Their research shows that novel exosome‐mediated delivery of survivin T34A mutant increases gemcitabine sensitivity in pancreatic adenocarcinoma. Current experimental stage, the methods commonly used in recent years include chemical linking of targeting peptides, modification of exosomal membranes or progenitor cells by genetic engineering, magnetic nanoparticle technology, electrostatic interaction, and postinsertion. These methods are all aimed for precisely target the therapeutic agent to the lesion. Applications of partial surface modification exosomes are summarized in Table 3.

TABLE 3 Clinical applications examples of exosome‐based therapies in cancers.

Target mode	Targeting method	Drug loading	Targeted tissues and applications	References	
Chemical reaction	Extracellular vesicles containing azide lipids were conjugated to the targeted peptide using copper‐free catalytic click chemistry.	PTX (loaded on liposomes)	Tumor cells	229	
Genetic engineering	Engineered mouse immature dendritic cells expressing with Lamp2b fused to iRGD peptide to generate tumor‐targeted exosomes.	DOX (electroporation)	Tumor tissues, suppress the growth of tumor	230	
Genetic engineering	In dendritic cells (dc), expression of the membrane protein‐containing fusion proteins Lamp2b and RVG peptides, as well as exosomes, are available from the cells by genetic modification.	siRNA (electroporation)	Targeting the central nervous system (neurons, microglia, oligodendrocytes) to treat Alzheimer's disease	231	
Genetic engineering	Donor cells were engineered to express platelet‐derived growth by targeting transmembrane domain factor receptors fused with GE11 peptides in order to absorb exosome sources from them.	let‐7a miRNA (transfection)	Breast cancer tissue targeted to express EGFR for breast cancer treatment	232	
Electrostatic interaction	Complexes formed by cationic lipids and sensitive fusion peptides bind exosomes through electrostatic interactions to target the receptor cell membranes.	Dextran, saponin (electroporation)	Targeting receptor cell membranes enhances cellular uptake and cytoplasmic release of exosomes	233	
Abbreviations: DOX, doxorubicin; PTX, paclitaxel; siRNA, short interfering RNA.

John Wiley & Sons, Ltd.

There are several challenges that need to be overcome to fully realize the potential of exosome‐based therapies in cancer patients. These include the optimization of exosome production and engineering, the identification of suitable cancer targets, and the development of strategies to overcome drug resistance and tumor heterogeneity. 45 Furthermore, targeting TAEs may also have diagnostic potential, as their cargo can reflect the molecular profile of the originating tumor. 234 This could allow for noninvasive monitoring of treatment response and disease progression. Overall, therapeutic targeting of TAEs holds great promise as a novel approach to cancer treatment, offering the potential for more effective and personalized therapies. With the continuous progress of science and technology and the deepening of clinical trials, we believe that exosomes will become one of the important tools for cancer treatment in the future.

6 CONCLUSIONS

Exosomes are vital carriers of information transmission between tumor cells, which affect the proliferation, metastasis, and invasion of cancer via regulating the microenvironment of tumor. 235 Research mechanism of exosomal in cancer has achieved notable breakthrough, such as the clinical application of antivascular and EGFR‐TKIs resistance mechanism. 236 Exosomes also play a crucial role in tumors combined with other diseases, such as some neuropsychiatric diseases 237 and ocular diseases. 238 It is believed that exosomes may be more widely applied in the clinical diagnosis, prognosis prediction and treatment of cancer in the near future.

Exosomes ncRNAs (miRNAs, lncRNAs, and other ncRNAs) act as an important role in cancer tumor progression (Figure 3). Cancer cells can secrete exosomes containing specific ncRNAs to other cancer cells, endothelial cells, mesenchymal cells, and immune cells, activate receptor cell signaling pathways, regulate the expression of target genes, induce angiogenesis, EMT, and immune escape, and so on, and promote the occurrence and development of cancer. 239 , 240 On the contrary, immune cells, mesenchymal cells, endothelial cells, and other stromal cells can also transmit exosomes to cancer cells, affecting the proliferation, invasion, and metastasis of tumor cells. 45 , 241 However, many people with cancer are diagnosed at an advanced stage. It is hoped that more comprehensive research on the pathogenesis of tumors by exosomes can make a breakthrough in the early diagnosis of tumors, and bring more benefits for the early detection, early diagnosis and early treatment of patients.

FIGURE 3 The function of exosome noncoding RNAs in cancer. Tumor cells secrete exosomes, which contain diverse nucleic acids (ncRNA) to modify tumors cells and stromal cells in the tumor progression such as endothelial cells to effect angiogenesis, tumor cells develop resistance to drugs, growth metastasis, and immune disorder.

In general, exosomes are important pathways for tumor cell information transmission. Nowadays, the study of exosomes in the mechanism of cancer has achieved many positive results. However, there is a lack of in‐depth systematic research at present. There are still many questions about tumor‐derived exosomes and mechanism of cancer metastasis. For instance, how tumor‐derived exosomes and cancer cells or host cells identify each other and how vesicle contents play a role in regulating tumor progression. Are there stronger genes signal in tumors than that derived from exosomes or expressed by metastatic tumor cells? Thus, there needs to be more researches on both the basic and clinical translational studies on exosomes and tumor. Given the role of exosomes, future researches will afford better guidance for the future diagnosis and treatment of cancer, especially the diagnosis and clinical treatment of progression of cancer.

AUTHOR CONTRIBUTIONS

Investigation and writing—original draft preparation: Xiaomin Liu, Fan Wu, Wei Pan, Guangchao Liu, Hui Zhang and Dawei Yan. Investigation and writing—review and editing: Xiaomin Liu, Fan Wu, Wei Pan, and Xiaojun Ren Conceptualization, investigation, writing—original draft preparation, supervision, and project administration: Zhongliang Ma, Xiaomin Liu, Fan Wu, Hui Zhang, Saijing Zheng and Xiaojun Ren All authors have read and agreed to the published version of the manuscript.

CONFLICT OF INTEREST STATEMENT

Authors X. M. L., G. C. L., H. Z., D. W. Y., and S. J. Z. are employees in Shanghai New Tobacco Product Research Institute Co., Ltd. The other authors have no conflict of interest to declare.

ETHICS STATEMENT

Ethics approval was not needed for this study.

ACKNOWLEDGMENTS

The authors are thankful for the financial support from the National Key Research and Development Program of China (2022YFA1603701), National Natural Science Foundation of China (22274004), R&D Program of Beijing Municipal Education Commission (KM202310005015) and Shanghai Science and Technology Committee (20S11901300). We acknowledge Linda (Ningjing) Ma (Mount Holyoke College) for critical reading of the manuscript. We acknowledged the tool of Figdraw for providing us with drawing tools and materials.

DATA AVAILABILITY STATEMENT

Not applicable.
==== Refs
REFERENCES

1 Jokhadze N , Das A , Dizon DS . Global cancer statistics: a healthy population relies on population health. CA Cancer J Clin. 2024;74 (3 ):224‐226.38572764
2 Thai AA , Solomon BJ , Sequist LV , Gainor JF , Heist RS . Lung cancer. Lancet. 2021;398 (10299 ):535‐554.34273294
3 Siegel RL , Giaquinto AN , Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024;74 (1 ):12‐49.38230766
4 Siegel RL , Jemal A , Wender RC , Gansler T , Ma J , Brawley OW . An assessment of progress in cancer control. CA Cancer J Clin. 2018;68 (5 ):329‐339.30191964
5 Jiang J , Mei J , Ma Y , et al. Tumor hijacks macrophages and microbiota through extracellular vesicles. Exploration. 2022;2 (1 ). doi:10.1002/exp.20210144
6 Li W , Liu JB , Hou LK , et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21 (1 ):25.35057806
7 Calvo‐Lozano O , Garcia‐Aparicio P , Raduly LZ , et al. One‐step and real‐time detection of microRNA‐21 in human samples for lung cancer biosensing diagnosis. Anal Chem. 2022;94 (42 ):14659‐14665.36219565
8 Kalluri R , LeBleu VS . The biology, function, and biomedical applications of exosomes. Science. 2020;367 (6478 ):eaau6977.32029601
9 Gurunathan S , Kang MH , Kim JH . A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes. Int J Nanomed. 2021;16 :1281‐1312.
10 Chen R , Xu X , Qian Z , et al. The biological functions and clinical applications of exosomes in lung cancer. Cell Mol Life Sci. 2019;76 (23 ):4613‐4633.31352532
11 Vanni I , Alama A , Grossi F , Dal Bello MG , Coco S . Exosomes: a new horizon in lung cancer. Drug Discovery Today. 2017;22 (6 ):927‐936.28288782
12 Hsu MT , Wang YK , Tseng YJ . Exosomal proteins and lipids as potential biomarkers for lung cancer diagnosis, prognosis, and treatment. Cancers. 2022;14 (3 ):732.35158999
13 Yin L , Liu X , Shao X , et al. The role of exosomes in lung cancer metastasis and clinical applications: an updated review. J Transl Med. 2021;19 (1 ):312.34281588
14 Li MY , Liu LZ , Dong M . Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Mol Cancer. 2021;20 (1 ):22.33504342
15 Zhuang J , Tan J , Wu C , et al. Extracellular vesicles engineered with valency‐controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy. Nucleic Acids Res. 2020;48 (16 ):8870‐8882.32810272
16 Yan H , Bu P . Non‐coding RNA in cancer. Essays Biochem. 2021;65 (4 ):625‐639.33860799
17 Panni S , Lovering RC , Porras P , Orchard S . Non‐coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech. 2020;1863 (6 ):194417.31493559
18 Anastasiadou E , Jacob LS , Slack FJ . Non‐coding RNA networks in cancer. Nat Rev Cancer. 2018;18 (1 ):5‐18.29170536
19 Yin X , Yang J , Wang H , et al. Non‐coding genome in small cell lung cancer between theoretical view and clinical applications. Semin Cancer Biol. 2022;86 (3 ):237‐250.35367369
20 Hermann DM , Xin W , Bahr M , Giebel B , Doeppner TR . Emerging roles of extracellular vesicle‐associated non‐coding RNAs in hypoxia: insights from cancer, myocardial infarction and ischemic stroke. Theranostics. 2022;12 (13 ):5776‐5802.35966580
21 Hu W , Liu C , Bi ZY , et al. Comprehensive landscape of extracellular vesicle‐derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol Cancer. 2020;19 (1 ):102.32503543
22 Xu K , Zhang C , Du T , et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134 :111111.33352449
23 Gulei D , Irimie AI , Cojocneanu‐Petric R , Schultze JL . Berindan‐Neagoe I. Exosomes‐small players, big sound. Bioconjugate Chem. 2018;29 (3 ):635‐648.
24 Reese M , Dhayat SA . Small extracellular vesicle non‐coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. J Hematol Oncol. 2021;14 (1 ):141.34496946
25 Zhou L , Lv T , Zhang Q , et al. The biology, function and clinical implications of exosomes in lung cancer. Cancer Lett. 2017;407 :84‐92.28807820
26 Colombo M , Raposo G , Thery C . Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30 :255‐289.25288114
27 Han QF , Li WJ , Hu KS , et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21 (1 ):207.36320056
28 Yu D , Li Y , Wang M , et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21 (1 ):56.35180868
29 Lai JJ , Chau ZL , Chen SY , et al. Exosome processing and characterization approaches for research and technology development. Adv Sci. 2022;9 (15 ):e2103222.
30 Sadeghi S , Tehrani FR , Tahmasebi S , Shafiee A , Hashemi SM . Exosome engineering in cell therapy and drug delivery. Inflammopharmacology. 2023;31 (1 ):145‐169.36609717
31 Zhou Y , Ren H , Dai B , et al. Hepatocellular carcinoma‐derived exosomal miRNA‐21 contributes to tumor progression by converting hepatocyte stellate cells to cancer‐associated fibroblasts. J Exp Clin Cancer Res. 2018;37 (1 ):324.30591064
32 Zhang H , Deng T , Ge S , et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination‐related USP7. Oncogene. 2019;38 (15 ):2844‐2859.30546088
33 Ye L , Zhang Q , Cheng Y , et al. Tumor‐derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM‐1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6 (1 ):145.30526680
34 Cheng L , Liu J , Liu Q , et al. Exosomes from melatonin treated hepatocellularcarcinoma cells alter the immunosupression status through STAT3 pathway in macrophages. Int J Biol Sci. 2017;13 (6 ):723‐734.28655998
35 Nakano T , Chen IH , Wang CC , et al. Circulating exosomal miR‐92b: its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence. Am J Transplant. 2019;19 (12 ):3250‐3262.31162867
36 Zhu M , Zhang N , Ma J , He S . Integration of exosomal miR‐106a and mesothelial cells facilitates gastric cancer peritoneal dissemination. Cell Signal. 2022;91 :110230.34958869
37 Zhu AK , Shan YQ , Zhang J , Liu XC , Ying RC , Kong WC . Exosomal NNMT from peritoneum lavage fluid promotes peritoneal metastasis in gastric cancer. Kaohsiung J Med Sci. 2021;37 (4 ):305‐313.33508890
38 Kimura Y , Ohzawa H , Miyato H , et al. Intraperitoneal transfer of microRNA‐29b‐containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer. Cancer Sci. 2023;114 (7 ):2939‐2950.36939028
39 Qiu S , Xie L , Lu C , et al. Gastric cancer‐derived exosomal miR‐519a‐3p promotes liver metastasis by inducing intrahepatic M2‐like macrophage‐mediated angiogenesis. J Exp Clin Cancer Res. 2022;41 (1 ):296.36217165
40 Yang J , Zhang X , Cao J , et al. Circular RNA UBE2Q2 promotes malignant progression of gastric cancer by regulating signal transducer and activator of transcription 3‐mediated autophagy and glycolysis. Cell Death Dis. 2021;12 (10 ):910.34611143
41 Zhang Z , Sun C , Zheng Y , Gong Y . circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR‐194‐5p. Cell Cycle. 2022;21 (20 ):2145‐2164.35708677
42 Zhang C , Luo Y , Cao J , Wang X , Miao Z , Shao G . Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR‐206 to upregulate NETO2 and FOXP1 expression. Cancer Med. 2020;9 (22 ):8600‐8611.33006432
43 Tian JW , Zhang HJ , Li SY , Guo YL , Chen G , Yu ZL . Tumor cell‐derived extracellular vesicles in modulating phenotypes and immune functions of macrophages: mechanisms and therapeutic applications. J Cancer. 2023;14 (8 ):1321‐1334.37283792
44 Li Y , Hu J , Wang M , et al. Exosomal circPABPC1 promotes colorectal cancer liver metastases by regulating HMGA2 in the nucleus and BMP4/ADAM19 in the cytoplasm. Cell Death Discov. 2022;8 (1 ):335.35871166
45 Mashouri L , Yousefi H , Aref AR , Ahadi AM , Molaei F , Alahari SK . Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18 (1 ):75.30940145
46 Tang Y , Cui Y , Li Z , et al. Radiation‐induced miR‐208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J Exp Clin Cancer Res. 2016;35 :7.26754670
47 Fan J , Xu G , Chang Z , Zhu L , Yao J . miR‐210 transferred by lung cancer cell‐derived exosomes may act as proangiogenic factor in cancer‐associated fibroblasts by modulating JAK2/STAT3 pathway. Clin Sci (Colch). 2020;134 (7 ):807‐825.32219336
48 You J , Li M , Cao LM , et al. Snail1‐dependent cancer‐associated fibroblasts induce epithelial‐mesenchymal transition in lung cancer cells via exosomes. QJM. 2019;112 (8 ):581‐590.31106370
49 Qi Y , Zha W , Zhang W . Exosomal miR‐660‐5p promotes tumor growth and metastasis in non‐small cell lung cancer. J BUON. 2019;24 (2 ):599‐607.31128012
50 You X , Guo Y , Liu X , Ma C . [Exosomes derived from LPS‐stimulated macrophages promote TGF‐beta1‐induced epithelial‐mesenchymal transition of human type II alveolar epithelial A549 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019;35 (8 ):673‐681.31638563
51 Mathieu M , Nevo N , Jouve M , et al. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat Commun. 2021;12 (1 ):4389.34282141
52 Yang Q , Xu J , Gu J , et al. Extracellular vesicles in cancer drug resistance: roles, mechanisms, and implications. Adv Sci. 2022;9 (34 ):e2201609.
53 Chen G , Huang AC , Zhang W , et al. Exosomal PD‐L1 contributes to immunosuppression and is associated with anti‐PD‐1 response. Nature. 2018;560 (7718 ):382‐386.30089911
54 de Miguel‐Perez D , Russo A , Arrieta O , et al. Extracellular vesicle PD‐L1 dynamics predict durable response to immune‐checkpoint inhibitors and survival in patients with non‐small cell lung cancer. J Exp Clin Cancer Res. 2022;41 (1 ):186.35650597
55 Asvapromtada S , Sonoda H , Kinouchi M , et al. Characterization of urinary exosomal release of aquaporin‐1 and ‐2 after renal ischemia‐reperfusion in rats. Am J Physiol Ren Physiol. 2018;314 (4 ):F584‐F601.
56 Wei H , Chen Q , Lin L , et al. Regulation of exosome production and cargo sorting. Int J Biol Sci. 2021;17 (1 ):163‐177.33390841
57 Xia X , Wang Y , Qin Y , Zhao S , Zheng JC . Exosome: a novel neurotransmission modulator or non‐canonical neurotransmitter? Ageing Res Rev. 2022;74 :101558.34990846
58 Mathieu M , Martin‐Jaular L , Lavieu G , Thery C . Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell‐to‐cell communication. Nat Cell Biol. 2019;21 (1 ):9‐17.30602770
59 Zeng Z , Li Y , Pan Y , et al. Cancer‐derived exosomal miR‐25‐3p promotes pre‐metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9 (1 ):5395.30568162
60 Lan J , Sun L , Xu F , et al. M2 macrophage‐derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 2019;79 (1 ):146‐158.30401711
61 Chen P , Li Y , Liu R , et al. Non‐small cell lung cancer‐derived exosomes promote proliferation, phagocytosis, and secretion of microglia via exosomal microRNA in the metastatic microenvironment. Transl Oncol. 2023;27 :101594.36463825
62 Fang T , Lv H , Lv G , et al. Tumor‐derived exosomal miR‐1247‐3p induces cancer‐associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9 (1 ):191.29335551
63 Zhang X , Sai B , Wang F , et al. Hypoxic BMSC‐derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3‐induced EMT. Mol Cancer. 2019;18 (1 ):40.30866952
64 Wang H , Yu L , Huang P , et al. Tumor‐associated exosomes are involved in hepatocellular carcinoma tumorigenesis, diagnosis, and treatment. J Clin Transl Hepatol. 2022;10 (3 ):496‐508.35836772
65 Wu M , Wang G , Hu W , Yao Y , Yu XF . Emerging roles and therapeutic value of exosomes in cancer metastasis. Mol Cancer. 2019;18 (1 ):53.30925925
66 Cazzoli R , Buttitta F , Di Nicola M , et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8 (9 ):1156‐1162.23945385
67 Liang M , Chen X , Wang L , et al. Cancer‐derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression. J Exp Clin Cancer Res. 2020;39 (1 ):176.32867817
68 Jiang C , Zhang N , Hu X , Wang H . Tumor‐associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer. 2021;20 (1 ):117.34511114
69 Silvestri R , Nicoli V , Gangadharannambiar P , Crea F , Bootman MD . Calcium signalling pathways in prostate cancer initiation and progression. Nat Rev Urol. 2023;20 (9 ):524‐543.36964408
70 Dewdney B , Jenkins MR , Best SA , et al. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress. Signal Transduct Target Ther. 2023;8 (1 ):400.37857607
71 Xiao H , Ye X , Vishwakarma V , Preet R , Dixon DA . CRC‐derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c‐Myc mRNA. Cancer Biol Ther. 2022;23 (1 ):139‐149.35130122
72 Deng Y , Liu X , Huang Y , et al. STIM1‐regulated exosomal EBV‐LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma. Cell Oncol. 2023;46 (4 ):987‐1000.
73 Harada T , Yamamoto H , Kishida S , et al. Wnt5b‐associated exosomes promote cancer cell migration and proliferation. Cancer Sci. 2017;108 (1 ):42‐52.27762090
74 Huang L , Wang F , Wang X , et al. M2‐like macrophage‐derived exosomes facilitate metastasis in non‐small‐cell lung cancer by delivering integrin alphaVbeta3. MedComm. 2023;4 (1 ):e191.36582304
75 Mutschelknaus L , Azimzadeh O , Heider T , et al. Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep. 2017;7 (1 ):12423.28963552
76 Altorki NK , Markowitz GJ , Gao D , et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19 (1 ):9‐31.30532012
77 Wang C , Xu J , Yuan D , et al. Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis. Mol Cell Biochem. 2020;469 (1‐2 ):77‐87.32297178
78 Becker A , Thakur BK , Weiss JM , Kim HS , Peinado H , Lyden D . Extracellular vesicles in cancer: cell‐to‐cell mediators of metastasis. Cancer Cell. 2016;30 (6 ):836‐848.27960084
79 Li I , Nabet BY . Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Mol Cancer. 2019;18 (1 ):32.30823926
80 Hashemi M , Khosroshahi EM , Chegini MK , et al. miRNAs and exosomal miRNAs in lung cancer: new emerging players in tumor progression and therapy response. Pathol Res Pract. 2023;251 :154906.37939448
81 Conway EM , Pikor LA , Kung SH , et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193 (2 ):116‐130.26583808
82 Mehla K , Singh PK . Metabolic regulation of macrophage polarization in cancer. Trends Cancer. 2019;5 (12 ):822‐834.31813459
83 Gambardella V , Castillo J , Tarazona N , et al. The role of tumor‐associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020;86 :102015.32248000
84 Han C , Zhang C , Wang H , Zhao L . Exosome‐mediated communication between tumor cells and tumor‐associated macrophages: implications for tumor microenvironment. Oncoimmunology. 2021;10 (1 ):1887552.33680573
85 Guo W , Li Y , Pang W , Shen H . Exosomes: a potential therapeutic tool targeting communications between tumor cells and macrophages. Mol Ther. 2020;28 (9 ):1953‐1964.32563274
86 Chen Q , Li Y , Gao W , Chen L , Xu W , Zhu X . Exosome‐mediated crosstalk between tumor and tumor‐associated macrophages. Front Mol Biosci. 2021;8 :764222.34722637
87 Zhou X , Hong Y , Liu Y , et al. Intervening in hnRNPA2B1‐mediated exosomal transfer of tumor‐suppressive miR‐184‐3p for tumor microenvironment regulation and cancer therapy. J Nanobiotechnol. 2023;21 (1 ):422.
88 Tan S , Yu H , Zhang Z , Liu Y , Lou G . Hypoxic tumour‐derived exosomal miR‐1225‐5p regulates M2 macrophage polarisation via toll‐like receptor 2 to promote ovarian cancer progress. Autoimmunity. 2023;56 (1 ):2281226.38010845
89 Zhu L , Yang Y , Li H , et al. Exosomal microRNAs induce tumor‐associated macrophages via PPARgamma during tumor progression in SHH medulloblastoma. Cancer Lett. 2022;535 :215630.35304257
90 Li M , Xu H , Qi Y , et al. Tumor‐derived exosomes deliver the tumor suppressor miR‐3591‐3p to induce M2 macrophage polarization and promote glioma progression. Oncogene. 2022;41 (41 ):4618‐4632.36085418
91 Zhao S , Mi Y , Guan B , et al. Tumor‐derived exosomal miR‐934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2020;13 (1 ):156.33213490
92 Chen J , Zhang K , Zhi Y , et al. Tumor‐derived exosomal miR‐19b‐3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. Clin Transl Med. 2021;11 (9 ):e478.34586722
93 Xu L , Wang L , Yang R , Li T , Zhu X . Lung adenocarcinoma cell‐derived exosomes promote M2 macrophage polarization through transmission of miR‐3153 to activate the JNK signaling pathway. Hum Mol Genet. 2023;32 (13 ):2162‐2176.37010098
94 Kong W , Zhang L , Chen Y , Yu Z , Zhao Z . Cancer cell‐derived exosomal LINC00313 induces M2 macrophage differentiation in non‐small cell lung cancer. Clin Transl Oncol. 2022;24 (12 ):2395‐2408.35980503
95 He Z , Wang J , Zhu C , et al. Exosome‐derived FGD5‐AS1 promotes tumor‐associated macrophage M2 polarization‐mediated pancreatic cancer cell proliferation and metastasis. Cancer Lett. 2022;548 :215751.35718269
96 Shen T , Miao S , Zhou Y , et al. Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3. Cell Commun Signal. 2022;20 (1 ):152.36153596
97 Xie S , Li X , Yan J , Yu H , Chen S , Chen K . Knockdown of liver cancer cell‐secreted exosomal PSMA5 controls macrophage polarization to restrain cancer progression by blocking JAK2/STAT3 signaling. Immun, Inflamm Disease. 2024;12 (2 ):e1146.
98 Ling HY , Yang Z , Wang PJ , et al. Diffuse large B‐cell lymphoma‐derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway. Chem Biol Interact. 2022;352 :109779.34922904
99 Gu L , Feng C , Li M , Hong Z , Di W , Qiu L . Exosomal NOX1 promotes tumor‐associated macrophage M2 polarization‐mediated cancer progression by stimulating ROS production in cervical cancer: a preliminary study. Eur J Med Res. 2023;28 (1 ):323.37679792
100 Rao X , Zhou X , Wang G , et al. NLRP6 is required for cancer‐derived exosome‐modified macrophage M2 polarization and promotes metastasis in small cell lung cancer. Cell Death Dis. 2022;13 (10 ):891.36270983
101 Kim H , Park HJ , Chang HW , et al. Exosome‐guided direct reprogramming of tumor‐associated macrophages from protumorigenic to antitumorigenic to fight cancer. Bioactive Mater. 2023;25 :527‐540.
102 Xiao M , Zhang J , Chen W , Chen W . M1‐like tumor‐associated macrophages activated by exosome‐transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2018;37 (1 ):143.29986759
103 Malmberg R , Zietse M , Dumoulin DW , et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost‐effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23 (12 ):e552‐e561.36455584
104 Carlino MS , Larkin J , Long GV . Immune checkpoint inhibitors in melanoma. Lancet. 2021;398 (10304 ):1002‐1014.34509219
105 Ramazi S , Daddzadi M , Sahafnejad Z , Allahverdi A . Epigenetic regulation in lung cancer. MedComm. 2023;4 (6 ):e401.37901797
106 Ang HL , Mohan CD , Shanmugam MK , et al. Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev. 2023;43 (4 ):1141‐1200.36929669
107 Neviani P , Wise PM , Murtadha M , et al. Natural killer‐derived exosomal miR‐186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res. 2019;79 (6 ):1151‐1164.30541743
108 Wang T , Zhang H . Exploring the roles and molecular mechanisms of RNA binding proteins in the sorting of noncoding RNAs into exosomes during tumor progression. J Adv Res. 2023.
109 Yang Q , Zhao S , Shi Z , et al. Chemotherapy‐elicited exosomal miR‐378a‐3p and miR‐378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40 (1 ):120.33823894
110 Kim DH , Park H , Choi YJ , et al. Exosomal miR‐1260b derived from non‐small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2. Cell Death Dis. 2021;12 (8 ):747.34321461
111 Zhang Z , Yin J , Lu C , Wei Y , Zeng A , You Y . Exosomal transfer of long non‐coding RNA SBF2‐AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res. 2019;38 (1 ):166.30992025
112 Li T , Tao Z , Zhu Y , et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple‐negative breast cancer. Cell Death Dis. 2021;12 (7 ):684.34238922
113 Gao Z , Han X , Zhu Y , et al. Drug‐resistant cancer cell‐derived exosomal EphA2 promotes breast cancer metastasis via the EphA2‐Ephrin A1 reverse signaling. Cell Death Dis. 2021;12 (5 ):414.33879771
114 Zhang C , Liu X , Jin S , Chen Y , Guo R . Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21 (1 ):47.35151318
115 Cao Y . Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129 (8 ):3006‐3017.31264969
116 Zhang H , Wang M , He Y , et al. Chemotoxicity‐induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells. Cell Death Dis. 2021;12 (12 ):1116.34845198
117 Li Z , Meng X , Wu P , et al. Glioblastoma cell‐derived lncRNA‐containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res. 2021;9 (12 ):1383‐1399.34667108
118 Kugeratski FG , Kalluri R . Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J. 2021;288 (1 ):10‐35.32910536
119 Jena BC , Mandal M . The emerging roles of exosomes in anti‐cancer drug resistance and tumor progression: an insight towards tumor‐microenvironment interaction. Biochim Biophys Acta Rev Cancer. 2021;1875 (1 ):188488.33271308
120 Zhang L , Yu D . Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871 (2 ):455‐468.31047959
121 Barros FM , Carneiro F , Machado JC , Melo SA . Exosomes and immune response in cancer: friends or foes? Front Immunol. 2018;9 :730.29696022
122 Yuan Y , Wang L , Ge D , et al. Exosomal O‐GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up‐regulation of PD‐1 in CD8(+) T cells. Cancer Lett. 2021;500 :98‐106.33307156
123 Clayton A , Mitchell JP , Court J , Linnane S , Mason MD , Tabi Z . Human tumor‐derived exosomes down‐modulate NKG2D expression. J Immunol. 2008;180 (11 ):7249‐7258.18490724
124 Ashiru O , Boutet P , Fernandez‐Messina L , et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010;70 (2 ):481‐489.20068167
125 Lundholm M , Schroder M , Nagaeva O , et al. Prostate tumor‐derived exosomes down‐regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 2014;9 (9 ):e108925.25268476
126 Ham S , Lima LG , Chai EPZ , et al. Breast cancer‐derived exosomes alter macrophage polarization via gp130/STAT3 signaling. Front Immunol. 2018;9 :871.29867925
127 Djebali S , Davis CA , Merkel A , et al. Landscape of transcription in human cells. Nature. 2012;489 (7414 ):101‐108.22955620
128 Fontemaggi G . Non‐coding RNA regulatory networks in post‐transcriptional regulation of VEGFA in cancer. IUBMB Life. 2023;75 (1 ):30‐39.35467790
129 Saw PE , Xu X , Chen J , Song EW . Non‐coding RNAs: the new central dogma of cancer biology. Sci China Life Sci. 2021;64 (1 ):22‐50.32930921
130 Toden S , Zumwalt TJ , Goel A . Non‐coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875 (1 ):188491.33316377
131 Mafi A , Keshavarzmotamed A , Hedayati N , et al. Melatonin targeting non‐coding RNAs in cancer: focus on mechanisms and potential therapeutic targets. Eur J Pharmacol. 2023;950 :175755.37119959
132 Fortunato O , Gasparini P , Boeri M , Sozzi G . Exo‐miRNAs as a new tool for liquid biopsy in lung cancer. Cancers. 2019;11 (6 ):888.31242686
133 Cheng L , Sharples RA , Scicluna BJ , Hill AF . Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell‐free blood. J Extracell Vesicles. 2014;3 :23743.
134 Lu TX , Rothenberg ME . MicroRNA. J Allergy Clin Immunol. 2018;141 (4 ):1202‐1207.29074454
135 Yang F , Ning Z , Ma L , et al. Exosomal miRNAs and miRNA dysregulation in cancer‐associated fibroblasts. Mol Cancer. 2017;16 (1 ):148.28851377
136 Mori MA , Ludwig RG , Garcia‐Martin R , Brandao BB , Kahn CR . Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab. 2019;30 (4 ):656‐673.31447320
137 Zhang C , Xiao X , Chen M , Aldharee H , Chen Y , Long W . Liver kinase B1 restoration promotes exosome secretion and motility of lung cancer cells. Oncol Rep. 2018;39 (1 ):376‐382.29138862
138 Jouida A , McCarthy C , Fabre A , Keane MP . Exosomes: a new perspective in EGFR‐mutated lung cancer. Cancer Metastasis Rev. 2021;40 (2 ):589‐601.33855679
139 Wang N , Guo W , Song X , et al. Tumor‐associated exosomal miRNA biomarkers to differentiate metastatic vs. nonmetastatic non‐small cell lung cancer. Clin Chem Lab Med. 2020;58 (9 ):1535‐1545.32271158
140 Li H , Xia M , Zheng S , et al. Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non‐small cell lung cancer with leptomeningeal metastases. Biotechnol Genet Eng Rev. 2023:1‐22.
141 Liu H , Li PW , Yang WQ , et al. Identification of non‐invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs. BMC Cancer. 2019;19 (1 ):129.30736753
142 Ravishankar H , Mangani AS , Phoebe Moses GL , et al. Serum exosomal miRNA as biomarkers for retinoblastoma. Exp Eye Res. 2020;199 :108184.32795526
143 Chen L , Cao P , Huang C , Wu Q , Chen S , Chen F . Serum exosomal miR‐7977 as a novel biomarker for lung adenocarcinoma. J Cell Biochem. 2020;121 (5‐6 ):3382‐3391.31898829
144 Han Z , Li Y , Zhang J , et al. Tumor‐derived circulating exosomal miR‐342‐5p and miR‐574‐5p as promising diagnostic biomarkers for early‐stage lung adenocarcinoma. Int J Med Sci. 2020;17 (10 ):1428‐1438.32624699
145 Wu J , Feng Z , Wang R , et al. Integration of bioinformatics analysis and experimental validation identifies plasma exosomal miR‐103b/877‐5p/29c‐5p as diagnostic biomarkers for early lung adenocarcinoma. Cancer Med. 2022;11 (23 ):4411‐4421.35585716
146 Zhang T , Zhang P , Li HX . CAFs‐derived exosomal miRNA‐130a confers cisplatin resistance of NSCLC cells through PUM2‐dependent packaging. Int J Nanomed. 2021;16 :561‐577.
147 Wu SG , Shih JY . Management of acquired resistance to EGFR TKI‐targeted therapy in advanced non‐small cell lung cancer. Mol Cancer. 2018;17 (1 ):38.29455650
148 Hisakane K , Seike M , Sugano T , et al. Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial‐mesenchymal transition in EGFR mutant non‐small cell lung cancer cells. Thorac Cancer. 2021;12 (11 ):1690‐1698.33939301
149 Zhang Y , Qian K , Liu X , Zhao X , Zhao T , Lu G . Exosomal mir‐625‐3p derived from hypoxic lung cancer cells facilitates metastasis by targeting SCAI. Mol Biol Rep. 2022;49 (10 ):9275‐9281.35988100
150 Mittal V . Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13 :395‐412.29414248
151 Tam WL , Weinberg RA . The epigenetics of epithelial‐mesenchymal plasticity in cancer. Nat Med. 2013;19 (11 ):1438‐1449.24202396
152 Zhou J , Wang H , Sun Q , et al. miR‐224‐5p‐enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non‐small cell lung cancer. Mol Ther Nucleic Acids. 2021;23 :1217‐1228.33664999
153 He S , Li Z , Yu Y , et al. Exosomal miR‐499a‐5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. Exp Cell Res. 2019;379 (2 ):203‐213.30978341
154 Liu XN , Zhang CB , Lin H , et al. microRNA‐204 shuttled by mesenchymal stem cell‐derived exosomes inhibits the migration and invasion of non‐small‐cell lung cancer cells via the KLF7/AKT/HIF‐1alpha axis. Neoplasma. 2021;68 (4 ):719‐731.33847133
155 Shao C , Huang Y , Fu B , et al. Targeting c‐Jun in A549 cancer cells exhibits antiangiogenic activity in vitro and in vivo through exosome/miRNA‐494‐3p/PTEN signal pathway. Front Oncol. 2021;11 :663183.33898323
156 Dai J , Su Y , Zhong S , et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5 (1 ):145.32759948
157 Li D , Meng D , Niu R . Exosome‐reversed chemoresistance to cisplatin in non‐small lung cancer through transferring miR‐613. Cancer Manag Res. 2020;12 :7961‐7972.32943930
158 Liu S , Wang W , Ning Y , et al. Exosome‐mediated miR‐7‐5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non‐small cell lung cancer. Cell Death Dis. 2022;13 (2 ):129.35136028
159 Jeong K , Yu YJ , You JY , Rhee WJ , Kim JA . Exosome‐mediated microRNA‐497 delivery for anti‐cancer therapy in a microfluidic 3D lung cancer model. Lab Chip. 2020;20 (3 ):548‐557.31942592
160 Rupaimoole R , Slack FJ . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16 (3 ):203‐222.28209991
161 Chen SW , Zhu SQ , Pei X , et al. Cancer cell‐derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti‐PD1 resistance by regulating the miR‐934/SHP2 axis in NSCLC. Mol Cancer. 2021;20 (1 ):144.34753486
162 Tyagi A , Wu SY , Sharma S , et al. Exosomal miR‐4466 from nicotine‐activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis. Oncogene. 2022;41 (22 ):3079‐3092.35461327
163 Zhao S , Mi Y , Guan B , et al. Correction to: tumor‐derived exosomal miR‐934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2021;14 (1 ):33.33618743
164 Zhao Y , Jin LJ , Zhang XY . Exosomal miRNA‐205 promotes breast cancer chemoresistance and tumorigenesis through E2F1. Aging. 2021;13 (14 ):18498‐18514.34292880
165 Liu X , Lu Y , Xu Y , et al. Exosomal transfer of miR‐501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459 :122‐134.31173853
166 Chen T , Liu Y , Chen J , Zheng H , Chen Q , Zhao J . Exosomal miR‐3180‐3p inhibits proliferation and metastasis of non‐small cell lung cancer by downregulating FOXP4. Thoracic Cancer. 2021;12 (3 ):372‐381.33350095
167 Song Z , Jia G , Ma P , Cang S . Exosomal miR‐4443 promotes cisplatin resistance in non‐small cell lung carcinoma by regulating FSP1 m6A modification‐mediated ferroptosis. Life Sci. 2021;276 :119399.33781830
168 Wu X , Bian B , Lin Z , et al. Identification of exosomal mRNA, lncRNA and circRNA signatures in an osteoarthritis synovial fluid‐exosomal study. Exp Cell Res. 2022;410 (1 ):112881.34780784
169 Chen Y , Wu Y , Guo L , et al. Exosomal Lnc NEAT1 from endothelial cells promote bone regeneration by regulating macrophage polarization via DDX3X/NLRP3 axis. J Nanobiotechnol. 2023;21 (1 ):98.
170 Banerjee M , Rajeswari VD . Critical review on the different roles of exosomes in TNBC and exosomal‐mediated delivery of microRNA/siRNA/lncRNA and drug targeting signalling pathways in triple‐negative breast cancer. Molecules. 2023;28 (4 ):1802.36838790
171 Ni J , Zhang X , Li J , et al. Tumour‐derived exosomal lncRNA‐SOX2OT promotes bone metastasis of non‐small cell lung cancer by targeting the miRNA‐194‐5p/RAC1 signalling axis in osteoclasts. Cell Death Dis. 2021;12 (7 ):662.34215717
172 Wu D , Deng S , Li L , et al. TGF‐beta1‐mediated exosomal lnc‐MMP2‐2 increases blood‐brain barrier permeability via the miRNA‐1207‐5p/EPB41L5 axis to promote non‐small cell lung cancer brain metastasis. Cell Death Dis. 2021;12 (8 ):721.34285192
173 Qu X , Liu B , Wang L , et al. Loss of cancer‐associated fibroblast‐derived exosomal DACT3‐AS1 promotes malignant transformation and ferroptosis‐mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat. 2023;68 :100936.36764075
174 Zhang R , Xia Y , Wang Z , et al. Serum long non coding RNA MALAT‐1 protected by exosomes is up‐regulated and promotes cell proliferation and migration in non‐small cell lung cancer. Biochem Biophys Res Commun. 2017;490 (2 ):406‐414.28623135
175 Feng Z , Li K , Qin K , et al. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. J Hematol Oncol. 2022;15 (1 ):112.35978332
176 Han M , Gu Y , Lu P , et al. Exosome‐mediated lncRNA AFAP1‐AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol Cancer. 2020;19 (1 ):26.32020881
177 Han M , Gu Y , Lu P , et al. Retraction Note to: exosome‐mediated lncRNA AFAP1‐AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol Cancer. 2022;21 (1 ):143.35820907
178 Castellano JJ , Marrades RM , Molins L , et al. Extracellular vesicle lincRNA‐p21 expression in tumor‐draining pulmonary vein defines prognosis in NSCLC and modulates endothelial cell behavior. Cancers. 2020;12 (3 ):734.32244977
179 Cheng Y , Dai X , Yang T , Zhang N , Liu Z , Jiang Y . Low long noncoding RNA growth arrest‐specific transcript 5 expression in the exosomes of lung cancer cells promotes tumor angiogenesis. J Oncol. 2019;2019 :2476175.31186629
180 Poulet C , Njock MS , Moermans C , et al. Exosomal long non‐coding RNAs in lung diseases. Int J Mol Sci. 2020;21 (10 ):3580.32438606
181 Yang Y , Jiang C , Yang Y , et al. Silencing of LncRNA‐HOTAIR decreases drug resistance of non‐small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 2018;497 (4 ):1003‐1010.29470986
182 Yu Z , Tang H , Chen S , et al. Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5‐induced autophagy. Drug Resist Updat. 2023;67 :100915.36641841
183 Zheng H , Chen C , Luo Y , et al. Tumor‐derived exosomal BCYRN1 activates WNT5A/VEGF‐C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. Clin Transl Med. 2021;11 (7 ):e497.34323412
184 Chen C , Luo Y , He W , et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest. 2020;130 (1 ):404‐421.31593555
185 Chen X , Deng R , Su D, et al. Visual genetic typing of glioma using proximity‐anchored in situ spectral coding amplification. Exploration. 2023;3 (5 ). doi:10.1002/exp.20220175
186 Wang FW , Cao CH , Han K , et al. APC‐activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. J Clin Invest. 2019;129 (2 ):727‐743.30511962
187 Lei Y , Guo W , Chen B , Chen L , Gong J , Li W . Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer. Oncol Rep. 2018;40 (6 ):3438‐3446.30542738
188 Zhang W , Cai X , Yu J , Lu X , Qian Q , Qian W . [Retracted] Exosome‑mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non‑small cell lung cancer. Int J Oncol. 2023;62 (1 ):10.36416342
189 Wang M , Zhou L , Yu F , Zhang Y , Li P , Wang K . The functional roles of exosomal long non‐coding RNAs in cancer. Cell Mol Life Sci. 2019;76 (11 ):2059‐2076.30683984
190 Wu DM , Deng SH , Liu T , Han R , Zhang T , Xu Y . TGF‐beta‐mediated exosomal lnc‐MMP2‐2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression. Cancer Med. 2018;7 (10 ):5118‐5129.30256540
191 Yu G , Jung H , Kang YY , Mok H . Comparative evaluation of cell‐ and serum‐derived exosomes to deliver immune stimulators to lymph nodes. Biomaterials. 2018;162 :71‐81.29438882
192 Zhang X , Xu Y , Ma L , et al. Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma. Cancer Commun. 2022;42 (4 ):287‐313.
193 Peng L , Cao Y , Hu C . Identification of exosomal circRNA CD226 as a potent driver of nonsmall cell lung cancer through miR‐1224‐3p/high mobility group AT‐hook 2 axis. Anticancer Drugs. 2022;33 (10 ):1126‐1138.35946568
194 Yang B , Teng F , Chang L , et al. Tumor‐derived exosomal circRNA_102481 contributes to EGFR‐TKIs resistance via the miR‐30a‐5p/ROR1 axis in non‐small cell lung cancer. Aging. 2021;13 (9 ):13264‐13286.33952725
195 Shao N , Song L , Sun X . Exosomal circ_PIP5K1A regulates the progression of non‐small cell lung cancer and cisplatin sensitivity by miR‐101/ABCC1 axis. Mol Cell Biochem. 2021;476 (6 ):2253‐2267.33570734
196 Kang Y , You J , Gan Y , et al. Serum and serum exosomal circRNAs hsa_circ_0001492, hsa_circ_0001439, and hsa_circ_0000896 as diagnostic biomarkers for lung adenocarcinoma. Front Oncol. 2022;12 :912246.35747792
197 Lee YS , Shibata Y , Malhotra A , Dutta A . A novel class of small RNAs: tRNA‐derived RNA fragments (tRFs). Genes Dev. 2009;23 (22 ):2639‐2649.19933153
198 Fagan SG , Helm M , Prehn JHM . tRNA‐derived fragments: a new class of non‐coding RNA with key roles in nervous system function and dysfunction. Prog Neurobiol. 2021;205 :102118.34245849
199 Zheng B , Song X , Wang L , et al. Plasma exosomal tRNA‐derived fragments as diagnostic biomarkers in non‐small cell lung cancer. Front Oncol. 2022;12 :1037523.36387119
200 Wang W , Zhu L , Li H , et al. Alveolar macrophage‐derived exosomal tRF‐22‐8BWS7K092 activates Hippo signaling pathway to induce ferroptosis in acute lung injury. Int Immunopharmacol. 2022;107 :108690.35299002
201 Shan S , Chen J , Sun Y , et al. Functionalized macrophage exosomes with panobinostat and PPM1D‐siRNA for diffuse intrinsic pontine gliomas therapy. Adv Sci. 2022;9 (21 ):e2200353.
202 Ha D , Yang N , Nadithe V . Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6 (4 ):287‐296.27471669
203 Wahlgren J , De LKT , Brisslert M , et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012;40 (17 ):e130.22618874
204 Didiot MC , Hall LM , Coles AH , et al. Exosome‐mediated delivery of hydrophobically modified siRNA for Huntingtin mRNA silencing. Mol Ther. 2016;24 (10 ):1836‐1847.27506293
205 Olejarz W , Dominiak A , Zolnierzak A , Kubiak‐Tomaszewska G , Lorenc T . Tumor‐derived exosomes in immunosuppression and immunotherapy. J Immunol Res. 2020;2020 :6272498.32537468
206 Lv B , Wang Y , Ma D , et al. Immunotherapy: reshape the tumor immune microenvironment. Front Immunol. 2022;13 :844142.35874717
207 Bai R , Cui J . Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing. Front Immunol. 2022;13 :890166.35833121
208 Yang F , Wang T , Du P , Fan H , Dong X , Guo H . M2 bone marrow‐derived macrophage‐derived exosomes shuffle microRNA‐21 to accelerate immune escape of glioma by modulating PEG3. Cancer Cell Int. 2020;20 :93.32231463
209 Lu L , Ling W , Ruan Z . TAM‐derived extracellular vesicles containing microRNA‐29a‐3p explain the deterioration of ovarian cancer. Mol Ther Nucleic Acids. 2021;25 :468‐482.34589270
210 Ye J , Liu X . Macrophage‐derived small extracellular vesicles in multiple diseases: biogenesis, function, and therapeutic applications. Front Cell Dev Biol. 2022;10 :913110.35832790
211 Zhou W , Zhou Y , Chen X , et al. Pancreatic cancer‐targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268 :120546.33253966
212 Donoso‐Quezada J , Ayala‐Mar S , Gonzalez‐Valdez J . The role of lipids in exosome biology and intercellular communication: function, analytics and applications. Traffic. 2021;22 (7 ):204‐220.34053166
213 Kamerkar S , LeBleu VS , Sugimoto H , et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546 (7659 ):498‐503.28607485
214 Qi R , Bai Y , Li K , et al. Cancer‐associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome‐derived ACSL4‐targeting miRNAs. Drug Resist Updat. 2023;68 :100960.37003125
215 Liu H , Chen L , Liu J , et al. Co‐delivery of tumor‐derived exosomes with alpha‐galactosylceramide on dendritic cell‐based immunotherapy for glioblastoma. Cancer Lett. 2017;411 :182‐190.28947140
216 Manfredi F , di Bonito P , Ridolfi B , et al. The CD8(+) T cell‐mediated immunity induced by HPV‐E6 uploaded in engineered exosomes is improved by ISCOMATRIX(TM) adjuvant. Vaccines. 2016;4 (4 ):42.27834857
217 Cheng B , Li C , Li J , et al. The activity and immune dynamics of PD‐1 inhibition on high‐risk pulmonary ground glass opacity lesions: insights from a single‐arm, phase II trial. Signal Transduct Target Ther. 2024;9 (1 ):93.38637495
218 Kato T , Mizutani K , Kameyama K , et al. Serum exosomal P‐glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Urol Oncol. 2015;33 (9 ):385. e15‐e20.
219 Lima LG , Leal AC , Vargas G , Porto‐Carreiro I , Monteiro RQ . Intercellular transfer of tissue factor via the uptake of tumor‐derived microvesicles. Thromb Res. 2013;132 (4 ):450‐456.23993901
220 Hao C , Sheng Z , Wang W , et al. Tumor‐derived exosomal miR‐148b‐3p mediates M2 macrophage polarization via TSC2/mTORC1 to promote breast cancer migration and invasion. Thorac Cancer. 2023;14 (16 ):1477‐1491.37144254
221 Thery C . Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011;3 :15.21876726
222 Iero M , Valenti R , Huber V , et al. Tumour‐released exosomes and their implications in cancer immunity. Cell Death Differ. 2008;15 (1 ):80‐88.17932500
223 Zhang Y , Bi J , Huang J , Tang Y , Du S , Li P . Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomed. 2020;15 :6917‐6934.
224 Zhou M , He X , Mei C , Ou C . Exosome derived from tumor‐associated macrophages: biogenesis, functions, and therapeutic implications in human cancers. Biomark Res. 2023;11 (1 ):100.37981718
225 Wei Q , Zhang J , Li Z , Wei L , Ren L . Serum Exo‐EphA2 as a potential diagnostic biomarker for pancreatic cancer. Pancreas. 2020;49 (9 ):1213‐1219.32898008
226 Li X , Wang Y , Xu C , et al. Analysis of competitive endogenous mechanism and survival prognosis of serum exosomes in ovarian cancer patients based on sequencing technology and bioinformatics. Front Genet. 2022;13 :850089.35910206
227 Le Naour J , Zitvogel L , Galluzzi L , Vacchelli E , Kroemer G . Trial watch: sTING agonists in cancer therapy. Oncoimmunology. 2020;9 (1 ):1777624.32934881
228 Aspe JR , Diaz Osterman CJ , Jutzy JM , Deshields S , Whang S , Wall NR . Enhancement of gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome‐mediated delivery of the Survivin‐T34A mutant. J Extracell Vesicles. 2014;3 :23244.
229 Lee J , Lee H , Goh U , et al. Cellular engineering with membrane fusogenic liposomes to produce functionalized extracellular vesicles. ACS Appl Mater Interfaces. 2016;8 (11 ):6790‐6795.26954538
230 Tian Y , Li S , Song J , et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35 (7 ):2383‐2390.24345736
231 Alvarez‐Erviti L , Seow Y , Yin H , Betts C , Lakhal S , Wood MJ . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29 (4 ):341‐345.21423189
232 Ohno S , Takanashi M , Sudo K , et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21 (1 ):185‐191.23032975
233 Nakase I , Futaki S . Combined treatment with a pH‐sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes. Sci Rep. 2015;5 :10112.26011176
234 Patel G , Agnihotri TG , Gitte M , et al. Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer. Cell Oncol. 2023;46 (5 ):1159‐1179.
235 Li B , Cao Y , Sun M , Feng H . Expression, regulation, and function of exosome‐derived miRNAs in cancer progression and therapy. FASEB J. 2021;35 (10 ):e21916.34510546
236 Liu X , Jiang T , Li X , et al. Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway. J Cell Mol Med. 2020;24 (2 ):1529‐1540.31894895
237 Si Q , Wu L , Pang D , Jiang P . Exosomes in brain diseases: pathogenesis and therapeutic targets. MedComm. 2023;4 (3 ):e287.37313330
238 Feng X , Peng Z , Yuan L , et al. Research progress of exosomes in pathogenesis, diagnosis, and treatment of ocular diseases. Front Bioeng Biotechnol. 2023;11 :1100310.36761297
239 Gu WJ , Shen YW , Zhang LJ , et al. The multifaceted involvement of exosomes in tumor progression: induction and inhibition. MedComm. 2021;2 (3 ):297‐314.34766148
240 Li K , Chen Y , Li A , Tan C , Liu X . Exosomes play roles in sequential processes of tumor metastasis. Int J Cancer. 2019;144 (7 ):1486‐1495.30155891
241 Greening DW , Gopal SK , Mathias RA , et al. Emerging roles of exosomes during epithelial‐mesenchymal transition and cancer progression. Semin Cell Dev Biol. 2015;40 :60‐71.25721809
